<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78012</article-id><article-id pub-id-type="doi">10.7554/eLife.78012</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Decoding mechanism of action and sensitivity to drug candidates from integrated transcriptome and chromatin state</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-270757"><name><surname>Carraro</surname><given-names>Caterina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3039-4675</contrib-id><email>caterina.carraro.2@phd.unipd.it</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-270914"><name><surname>Bonaguro</surname><given-names>Lorenzo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9675-7208</contrib-id><email>lorenzobonaguro@uni-bonn.de</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-270915"><name><surname>Schulte-Schrepping</surname><given-names>Jonas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270916"><name><surname>Horne</surname><given-names>Arik</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270917"><name><surname>Oestreich</surname><given-names>Marie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270918"><name><surname>Warnat-Herresthal</surname><given-names>Stefanie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270919"><name><surname>Helbing</surname><given-names>Tim</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1284-3254</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270920"><name><surname>De Franco</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270921"><name><surname>Haendler</surname><given-names>Kristian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270922"><name><surname>Mukherjee</surname><given-names>Sach</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270923"><name><surname>Ulas</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270924"><name><surname>Gandin</surname><given-names>Valentina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270925"><name><surname>Goettlich</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-268057"><name><surname>Aschenbrenner</surname><given-names>Anna C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9429-5457</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288948"><name><surname>Schultze</surname><given-names>Joachim L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228707"><name><surname>Gatto</surname><given-names>Barbara</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9465-6913</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00240q980</institution-id><institution>Department of Pharmaceutical and Pharmacological Sciences, University of Padova</institution></institution-wrap><addr-line><named-content content-type="city">Padova</named-content></addr-line><country>Italy</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043j0f473</institution-id><institution>Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) e.V.</institution></institution-wrap><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041nas322</institution-id><institution>Genomics and Immunoregulation, Life &amp; Medical Sciences (LIMES) Institute, University of Bonn</institution></institution-wrap><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/033eqas34</institution-id><institution>Institute of Organic Chemistry, Justus Liebig University Giessen</institution></institution-wrap><addr-line><named-content content-type="city">Giessen</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041nas322</institution-id><institution>PRECISE Platform for Genomics and Epigenomics, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) e.V. and University of Bonn</institution></institution-wrap><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t3r8h32</institution-id><institution>Institute of Human Genetics, University of Lübeck</institution></institution-wrap><addr-line><named-content content-type="city">Lübeck</named-content></addr-line><country>Germany</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043j0f473</institution-id><institution>Statistics and Machine Learning, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) e.V.</institution></institution-wrap><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>MRC Biostatistics Unit, University of Cambridge</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/016xsfp80</institution-id><institution>Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>31</day><month>08</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e78012</elocation-id><history><date date-type="received" iso-8601-date="2022-02-18"><day>18</day><month>02</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-08-15"><day>15</day><month>08</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-02-21"><day>21</day><month>02</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.02.21.481294"/></event></pub-history><permissions><copyright-statement>© 2022, Carraro et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Carraro et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-78012-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-78012-figures-v1.pdf"/><abstract><p>Omics-based technologies are driving major advances in precision medicine, but efforts are still required to consolidate their use in drug discovery. In this work, we exemplify the use of multi-omics to support the development of 3-chloropiperidines, a new class of candidate anticancer agents. Combined analyses of transcriptome and chromatin accessibility elucidated the mechanisms underlying sensitivity to test agents. Furthermore, we implemented a new versatile strategy for the integration of RNA- and ATAC-seq (Assay for Transposase-Accessible Chromatin) data, able to accelerate and extend the standalone analyses of distinct omic layers. This platform guided the construction of a perturbation-informed basal signature predicting cancer cell lines’ sensitivity and to further direct compound development against specific tumor types. Overall, this approach offers a scalable pipeline to support the early phases of drug discovery, understanding of mechanisms, and potentially inform the positioning of therapeutics in the clinic.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>drug candidate</kwd><kwd>sensitivity ML prediction</kwd><kwd>mechanism of action</kwd><kwd>multi-omics</kwd><kwd>transcriptome</kwd><kwd>chromatin accessibility</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001656</institution-id><institution>Helmholtz Association</institution></institution-wrap></funding-source><award-id>HGF Helmholtz AI grant Pro-Gene-Gen (ZT-I-PF5-23)</award-id><principal-award-recipient><name><surname>Oestreich</surname><given-names>Marie</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>German Research Foundation (DFG) Excellence Strategy (EXC2151-390873048)</award-id><principal-award-recipient><name><surname>Schultze</surname><given-names>Joachim L</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>German Research Foundation (DFG) - SCHU 950/8-1</award-id><principal-award-recipient><name><surname>Schultze</surname><given-names>Joachim L</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>German Research Foundation (DFG) - GRK 2168</award-id><principal-award-recipient><name><surname>Schultze</surname><given-names>Joachim L</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>German Research Foundation (DFG) - TP11</award-id><principal-award-recipient><name><surname>Schultze</surname><given-names>Joachim L</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>German Research Foundation (DFG) - SFB704</award-id><principal-award-recipient><name><surname>Schultze</surname><given-names>Joachim L</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002347</institution-id><institution>Bundesministerium für Bildung und Forschung</institution></institution-wrap></funding-source><award-id>BMBF-funded excellence project Diet-Body-Brain (DietBB)</award-id><principal-award-recipient><name><surname>Schultze</surname><given-names>Joachim L</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010661</institution-id><institution>Horizon 2020 Framework Programme</institution></institution-wrap></funding-source><award-id>EU project SYSCID under grant number 733100</award-id><principal-award-recipient><name><surname>Schultze</surname><given-names>Joachim L</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Combined analyses of transcriptome and chromatin accessibility elucidated the mechanisms underlying cancer cell lines response to antitumor candidates and provided a versatile perturbation-informed basal signature able to predict drug sensitivity.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Omic technologies have revolutionized the classical hypothesis<italic>-</italic>driven paradigm of drug discovery, offering a new perspective for the systematic identification of targets and therapeutics (<xref ref-type="bibr" rid="bib22">Dugger et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Paananen and Fortino, 2020</xref>). An increasing number of examples describe the use of these approaches to inspect the pharmacological profile of existing drugs, e.g., mechanism of action (MoA) and specific sensitivity biomarkers, as well as to assist their correct repositioning in clinical practice (<xref ref-type="bibr" rid="bib44">Koromina et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Matthews et al., 2016</xref>; <xref ref-type="bibr" rid="bib67">Mun et al., 2020</xref>; <xref ref-type="bibr" rid="bib104">Tsimberidou, 2015</xref>). Compared to traditional approaches, omics-based methods capture the complexity of biological systems and pathological processes in its entirety at increasingly affordable costs (<xref ref-type="bibr" rid="bib61">Matthews et al., 2016</xref>). Indeed, significant cost reductions have been announced for sequencing technologies, making them accessible to the scientific community with no impact on their robustness (<xref ref-type="bibr" rid="bib75">Pennisi, 2022</xref>). For this reason, refined strategies to handle the high-dimensional information of omics data are continuously investigated to expedite their routine use in preclinical drug development (<xref ref-type="bibr" rid="bib41">Kagohara et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib55">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib63">McFarland et al., 2020</xref>; <xref ref-type="bibr" rid="bib84">Rendeiro et al., 2020</xref>; <xref ref-type="bibr" rid="bib92">Shaheen et al., 2018</xref>; <xref ref-type="bibr" rid="bib97">Srivatsan et al., 2020</xref>; <xref ref-type="bibr" rid="bib117">Ye et al., 2018</xref>).</p><p>Studies from our group highlighted 3-chloropiperidines (3-CePs) as a novel class of candidate anticancer agents developed to improve the pharmacological profile of nitrogen mustard-based chemotherapeutics, characterized by a fast and affordable synthesis (<xref ref-type="bibr" rid="bib15">Carraro et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Carraro et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Helbing et al., 2020</xref>; <xref ref-type="bibr" rid="bib96">Sosic et al., 2017</xref>; <xref ref-type="bibr" rid="bib122">Zuravka et al., 2015a</xref>; <xref ref-type="bibr" rid="bib121">Zuravka et al., 2014</xref>; <xref ref-type="bibr" rid="bib123">Zuravka et al., 2015b</xref>). As intended, these agents were demonstrated to induce DNA lesions, a mechanism conceivably responsible for their cytotoxicity on tested cancer cell lines (<xref ref-type="bibr" rid="bib15">Carraro et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Carraro et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Helbing et al., 2020</xref>). Interestingly, despite their expected broad-acting MoA, a subset of derivatives showed preferential activity against pancreatic adenocarcinoma (PAAD)BxPC-3 cells in 2D and 3D cell culture when compared to other treatment-resistant cell lines (e.g. HCT-15 from colorectal cancer). This preferential activity requires more investigation for further preclinical and clinical translation, especially in light of the broad resistance of pancreatic tumors to most of the available treatments (<xref ref-type="bibr" rid="bib15">Carraro et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Carraro et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Helbing et al., 2020</xref>).</p><p>The contribution of multi-omics to support early phases of drug discovery is growing exponentially in the era of precision medicine (<xref ref-type="bibr" rid="bib55">Li et al., 2021</xref>). Combined omics technologies have the potential to address some of the intrinsic difficulties of the traditional drug discovery and development path, assisting it early from target prioritization and hit identification up to the evaluation of candidates’ efficacy and safety (<xref ref-type="bibr" rid="bib67">Mun et al., 2020</xref>). Drug-perturbation experiments have been employed to inspect the functionality of target proteins (<xref ref-type="bibr" rid="bib25">Faivre et al., 2020</xref>) and the MoA of therapeutics, efficiently guiding the decision-making process in the development of lead compounds (<xref ref-type="bibr" rid="bib67">Mun et al., 2020</xref>). The massive accumulation of genomic and transcriptomic profiles offers a precious substrate for the optimization of strategies capable of predicting susceptibility to known therapeutics (<xref ref-type="bibr" rid="bib4">Barretina et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Lamb et al., 2006</xref>; <xref ref-type="bibr" rid="bib99">Subramanian et al., 2017</xref>; <xref ref-type="bibr" rid="bib108">Uhlen et al., 2017</xref>). These approaches are further refined by the continuous acquisition of data from high-throughput single-cell platforms (<xref ref-type="bibr" rid="bib11">Bush et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Corsello et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">McFarland et al., 2020</xref>; <xref ref-type="bibr" rid="bib97">Srivatsan et al., 2020</xref>; <xref ref-type="bibr" rid="bib117">Ye et al., 2018</xref>). Beyond the most common transcriptome analysis, changes in gene regulation can be evaluated in terms of chromatin accessibility (<xref ref-type="bibr" rid="bib9">Buenrostro et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Granja et al., 2019</xref>; <xref ref-type="bibr" rid="bib88">Schmidl et al., 2019</xref>). We hypothesized that combining the information from the transcriptome and chromatin state would enable a higher-resolution and extremely robust mapping of cell dynamics upon drug exposure. Examples of the joint use of these two omic techniques exist (<xref ref-type="bibr" rid="bib41">Kagohara et al., 2020</xref>; <xref ref-type="bibr" rid="bib84">Rendeiro et al., 2020</xref>; <xref ref-type="bibr" rid="bib100">Suzuki et al., 2019</xref>; <xref ref-type="bibr" rid="bib106">Tung et al., 2021</xref>), but their synergistic employment on compounds under early development is still underexplored (<xref ref-type="bibr" rid="bib61">Matthews et al., 2016</xref>).</p><p>In this study, representative mono- (<bold>M</bold>) and bi-functional (<bold>B</bold>) 3-CePs bearing a single or double alkylating units (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) were selected to exemplify the use of a multi-omic approach to investigate the molecular determinants of susceptibility to novel drug candidates and their MoA (<xref ref-type="bibr" rid="bib15">Carraro et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Carraro et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Helbing et al., 2020</xref>). We analyzed transcriptional changes and chromatin status of cancer cell lines previously identified as high- (PAAD BxPC-3) and low-sensitive (colorectal adenocarcinoma HCT-15) after treatment by RNA- and ATAC-seq. In addition, we implemented our multi-omics pipeline in drug discovery to derive perturbation-informed signatures predicting compound sensitivity. We validated the approach by assessing cancer cell sensitivity to both the early-discovered compound <bold>M</bold> and the established antineoplastic agent cisplatin. Overall, the proposed pipeline not only allowed to identify potentially more susceptible target tumor types for further development of test compounds, but also offered a complete predictive framework to support precision oncology in a clinical setting.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cancer tropism of 3-chloropiperidines (3-CePs) is not explained by DNA damage.</title><p>(<bold>A</bold>) Chemical structure of the analyzed 3-CePs (M=monofunctional and B=bifunctional). (<bold>B</bold>) Quantification of genomic DNA damage in BxPC-3 and HCT-15 cells treated with M (10 nM and 100 nM), B (200 nM and 2 µM), or DMSO (dimethyl sulfoxide) 0.5% (ctrl) for 6 hr and analyzed by the fast micromethod single-strand-break assay: alkaline denaturation of DNA is followed in time up to 20 min by monitoring the fluorescence of the dsDNA-specific PicoGreen dye. (<bold>C</bold>) Cell cycle distribution (accumulation in G1 vs G2/S phases) of BxPC-3 and HCT-15 cells treated with M (10 nM), B (200 nM), or DMSO 0.5% for 6 hr and 72 hr analyzed by FACS (Fluorescence Activated Cell Sorting). At least three biological replicates were obtained per condition and unpaired two-tailed Student’s <italic>t</italic>-test was performed to assess statistical significance (p&lt;0.05). (<bold>D</bold>) Analysis of H2AX phosphorylation in BxPC-3 and HCT-15 cells treated with M (10 nM), B (200 nM), or DMSO 0.5% for 6 hr and 12 hr analyzed by FACS. At least three biological replicates were obtained per condition, and unpaired two-tailed Student’s <italic>t</italic>-test was performed to assess statistical significance (p&lt;0.05). (<bold>E</bold>) Schematic representation of the adopted omic-based approach.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Cancer tropism of 3-CePs is not explained by DNA damage—supporting data.</title><p>(<bold>A</bold>) Flow cytometry gating strategy for the cell cycle analysis and γH2AX induction. (<bold>B</bold>) Cell cycle distribution (accumulation in G1 vs G2/S phases) of BxPC-3 and HCT-15 cells treated with M (10 nM), B (200 nM), or DMSO 0.5% for 12 hr analyzed by FACS. At least three biological replicates were obtained per condition, and unpaired two-tailed Student’s <italic>t</italic>-test was performed to assess statistical significance (p&lt;0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Cancer tropism of 3-CePs is not explained by DNA damage</title><p>The selected <bold>M</bold> and <bold>B</bold>3-CePs (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) were shown in previous work to be particularly active in the nanomolar range against BxPC-3 PAAD cells (<xref ref-type="bibr" rid="bib14">Carraro et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Helbing et al., 2020</xref>). From this premise, the two compounds were chosen along with the highly sensitive BxPC-3 cell line and the low-sensitive HCT-15 colorectal adenocarcinoma cell line (72 hr IC<sub>50</sub> HCT-15/IC<sub>50</sub> BxPC-3: 50 for <bold>M</bold>, 10 for <bold>B</bold>) (<xref ref-type="bibr" rid="bib14">Carraro et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Helbing et al., 2020</xref>) to illustrate how integrative omics approaches unveil the molecular mechanisms responsible for the described cellular tropism.</p><p>First, to assess whether 3-CePs-induced DNA damage itself would differ in the two cell lines upon treatment, we measured the accumulation of DNA single-strand breaks after 6 hr of treatment with both compounds at their cytotoxicity IC<sub>50</sub>s in BxPC-3 and at a 10-times higher concentration (10 nM and 100 nM <bold>M;</bold> 200 nM and 2 µM <bold>B</bold>) (<xref ref-type="bibr" rid="bib89">Schröder et al., 2006</xref>). Surprisingly, the two cell lines showed very comparable DNA damage accumulation, in both cases higher after treatment with <bold>M</bold> compared to <bold>B</bold> (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). These results clearly pointed toward differential responses in the two cell lines downstream of DNA damage.</p><p>Since alkylating agents are known to alter the progression of the cell cycle (<xref ref-type="bibr" rid="bib42">Kaufmann and Paules, 1996</xref>; <xref ref-type="bibr" rid="bib65">Meyn and Murray, 1984</xref>; <xref ref-type="bibr" rid="bib105">Tu et al., 2004</xref>), we next performed a cell cycle distribution analysis by flow cytometry after different times of treatment (6 hr, 12 hr, and 72 hr) with both compounds (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> and B). While <bold>M</bold> induced a persisting block in G1 throughout the observation time in BxPC-3 cells, this block was absent in HCT-15 cells. In contrast, <bold>B</bold> induced an early G2/S block in HCT-15 cells (6 hr), which was not observed at later time points, while such a block was most obvious at 12 hr for BxPC-3 cells. Despite similar DNA damage accumulation, these findings clearly indicated a different behavior for the two cancer cell lines in terms of cell cycle progression after treatment with the two 3-CePs.</p><p>To determine the additional mechanisms explaining differential sensitivity to 3-CePs, we measured the activation of the DNA repair machinery as another key aspect in the cellular response to genotoxicants (<xref ref-type="bibr" rid="bib54">Li et al., 2020</xref>). To verify the ability of the two cancer cell lines to detect double-strand breaks (DSBs), we assessed the phosphorylation of H2AX (γH2AX), an early event of the DNA damage response (DDR) (<xref ref-type="bibr" rid="bib93">Sharma et al., 2012</xref>), by flow cytometry after 6 hr and 12 hr of treatment with both agents (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Interestingly, despite the comparable DNA damage accumulation in the two cell lines, only HCT-15 showed an increase in the γH2AX-positive population, suggesting a more efficient engagement of the DNA repair machinery.</p><p>Taken together, these results indicated that cell-specific mechanisms after the first event of DNA damage are responsible for the different sensitivity to 3-CePs.</p></sec><sec id="s2-2"><title>Treatments elicit cell-specific transcriptional changes</title><p>Different genetic and epigenetic factors define the responsiveness of tumor cells to chemotherapeutic agents (<xref ref-type="bibr" rid="bib110">Vasan et al., 2019</xref>). To address these globally, we analyzed changes in the transcriptome of the high- and low-sensitive cell lines after treatment with the two 3-CePs (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). RNA-seq was performed on total RNA of HCT-15 and BxPC-3 cells exposed to DMSO 0.5% (control) or treated with <bold>M</bold> (10 nM) or <bold>B</bold> (200 nM) for 6 hr and 12 hr (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) as in previous experiments.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Treatments elicit cell-specific transcriptional changes.</title><p>(<bold>A</bold>) An overview of the applied workflow for the RNA-seq analysis. (<bold>B</bold>) Number of up- (red) and down-regulated (blue) differential expression (DE) genes in BxPC-3 and HCT-15 cells after treatment with M (10 nM), B (200 nM), or DMSO 0.5% (ctrl) for 6 hr and 12 hr (adjusted p threshold = 0.05, shrinkage = TRUE, and multiple testing method = independent hypothesis weighting [IHW]). (<bold>C</bold>) Gene ontology (GO) database functional enrichment gene set enrichment analysis (GSEA) on cell-specific and shared up- and down-regulated DE genes. For each identified biological process, enrichments in terms of count and p-value of representative terms are reported (p&lt;0.05). (<bold>D</bold>) Expression level of cell-specific 6 hr DE genes across test conditions. GSEA was performed on modules with similar regulation identified by hierarchical clustering: for each cluster, representative GO terms and genes of the associated load are reported.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Treatments elicit cell-specific transcriptional changes—supporting data.</title><p>(<bold>A</bold>) Scheme of the applied workflow for the RNA-seq analyses. (<bold>B</bold>) Principal component analysis (PCA) post surrogate variable analysis (SVA) batch correction of RNA-seq data: PC1 vs PC2 showed sample separation by cell line, PC2 vs PC3 (cell lines depicted separately) showed treatment and time point separation. (<bold>C</bold>) Volcano plots reporting up- and down-regulated differential expression (DE) genes in all treated vs control comparisons (adjusted p&lt;0.05). (<bold>D</bold>) Venn plot reporting the number of specific and shared up- and down-regulated DE genes between BxPC-3 and HCT-15 cells (union of DE genes in all treated vs control comparisons). (<bold>E</bold>) Enriched gene ontology (GO) terms (p&lt;0.05) derived from gene set enrichment analysis (GSEA) on BxPC-3 and HCT-15 DE genes (union of DE genes in all treated vs control comparisons) and on shared DE genes (up- and down-regulated separately). (<bold>F</bold>) Schematic representation of enrichment map-based selection of representative GO terms to be reported in <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Treatments elicit cell-specific transcriptional changes—supporting data 2.</title><p>(<bold>A</bold>) Expression level of cell-specific 12 hr differential expression (DE) genes across test conditions. Gene set enrichment analysis (GSEA) was performed on modules with similar regulation identified by hierarchical clustering: for each cluster, representative gene ontology (GO) terms and genes of the associated load are reported. (<bold>B</bold>) GO database functional enrichment (GSEA) obtained from log<sub>2</sub>FC ranks in all treated vs control comparison both in BxPC-3 and HCT-15 cells. For each identified biological process, enrichments in terms of absolute normalized enrichment score (abs[NES]) and -log(p) of representative terms are reported (p&lt;0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig2-figsupp2-v1.tif"/></fig></fig-group><p>Principal component analysis (PCA) of all transcripts separated samples within each cell line according to treatment and time point (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), suggesting a clear transcriptional reprogramming after treatment. In fact, differential expression (DE) analysis showed that the expression of a large number of genes changed significantly in both cell lines after exposure to 3-CePs (p&lt;0.05, independent hypothesis weighting [IHW] multiple testing correction) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>), especially at 6 hr in BxPC-3 cells and upon treatment with <bold>B</bold> in HCT-15 cells.</p><p>Gene ontology (GO) enrichment was performed on the DE genes to determine signaling pathways and transcriptional programs explaining the observed differences. In a first explorative approach, we generated the union of DE genes per cell line irrespective of compound and time point, which allowed us also to distinguish between cell type-specific and shared DE genes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). The most representative biological processes identified by this analysis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) are reported in <xref ref-type="fig" rid="fig2">Figure 2C</xref> (see Methods and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref> for further details).</p><p>Unexpectedly, we identified a strong translational response in BxPC-3 cells after treatment, a process which is typically attenuated in stress conditions, as was the exposure to our DNA damaging agents, to allow proper recovery of the protein quality control machinery (<xref ref-type="bibr" rid="bib10">Burger et al., 2010</xref>; <xref ref-type="bibr" rid="bib94">Shenton et al., 2006</xref>). In contrast, a strong regulation of genes mediating protein stability and catabolism was observed in the low-sensitive cell line. In addition, HCT-15 cells activated genes involved in the DDR, consistent with their higher ability to detect and respond to DSBs. Both these two mechanisms pointed toward the activation of an adaptive stress response in the low-sensitive cell line.</p><p>To further characterize these transcriptional changes over time in a cell type-specific context, we grouped the DE genes at 6 hr and 12 hr in modules according to the similarity in their expression profiles and performed a functional enrichment on genes with similar expression patterns (<xref ref-type="fig" rid="fig2">Figure 2D</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Genes involved in ribosome biogenesis and DNA repair turned out to be upregulated, particularly after 6 hr of treatment in BxPC-3 cells (Clusters 2 and 3, <xref ref-type="fig" rid="fig2">Figure 2D</xref>). Besides, silencing of pro-survival genes involved in microtubule organization and the JAK-STAT cascade (Cluster 1, <xref ref-type="fig" rid="fig2">Figure 2D</xref>) was detected at the same time point. Only after 12 hr of treatment (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>), BxPC-3 cells boosted carbohydrate metabolism, most likely an attempt to recover in extremis (<xref ref-type="bibr" rid="bib56">Lin et al., 2020</xref>).</p><p>Also, HCT-15 cells upregulated clusters of genes mediating DNA repair, protein stability, and mitochondrial activity as early as 6 hr of treatment, suggesting this time point as the most informative to describe the response to 3-CePs (Clusters 4 and 6, <xref ref-type="fig" rid="fig2">Figure 2D</xref>). In contrast to BxPC-3 cells, HCT-15 downregulated genes involved in translation and ribosome biogenesis from 6 hr of exposure (Cluster 7, <xref ref-type="fig" rid="fig2">Figure 2D</xref>), while intensifying their response to oxidative stress after 12 hr (Cluster 17, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>).</p><p>This exploratory analysis showed clearly different transcriptional responses and distinct time dynamics in BxPC-3 compared to HCT-15 cells, most likely responsible for their different susceptibility to 3-CePs. In particular, our findings pointed toward DNA repair and proteostasis as key mechanisms tuning sensitivity to the compounds, as further confirmed by inspecting the complete rank of DE genes via gene set enrichment analysis (GSEA, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>; <xref ref-type="bibr" rid="bib98">Subramanian et al., 2005</xref>).</p></sec><sec id="s2-3"><title>DNA repair and proteostasis are key modulators of the response to 3-CePs</title><p>For their key role in the response to 3-CePs, DNA repair and protein homeostasis were further analyzed to clarify their contribution to BxPC-3 sensitivity.</p><p>Interestingly, DNA repair was activated in both cell lines early after 6 hr of treatment but with a different modulation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). First, base-excision repair (BER) was suggested as the preferential pathway of BxPC-3 by GO enrichment, while HCT-15 relied mostly on nucleotide-excision repair (NER), unleashing a generally stronger activation of the DDR. In detail, HCT-15 DE genes contributing to the response to the DNA damage stimulus were strongly upregulated already after 6 hr especially in response to <bold>B</bold>, while activated only after 12 hr in BxPC-3 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). In contrast, genes such as <italic>PPP4R2</italic> and <italic>RAD51AP1</italic>, both involved in the first phases of DSBs repair (<xref ref-type="bibr" rid="bib19">Chowdhury et al., 2008</xref>; <xref ref-type="bibr" rid="bib66">Modesti et al., 2007</xref>), were even downregulated in BxPC-3 cells at 6 hr.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>DNA repair and proteostasis are key modulators of the response to 3-chloropiperidines (3-CePs).</title><p>(<bold>A</bold>) Gene set enrichment analysis (GSEA) for terms related to DNA damage and repair performed on differential expression (DE) genes detected in each of the considered treated vs control comparisons. For each gene ontology (GO) term (p&lt;0.05), enrichments in terms of count and p-value are reported. (<bold>B</bold>) GSEA enrichment plots for the DNA repair pathway obtained from log<sub>2</sub>FC ranks for each of the considered treated vs control comparisons. The expression of leading edge genes is also shown, where key DE genes are reported with the same color of their associated DNA repair pathways (BER = base excision repair, NER = nucleotide-excision repair, MMR = mismatch repair, HR = homologous recombination, NHEJ = non-homologous end joining, and FA = Fanconi anemia pathway) (<xref ref-type="bibr" rid="bib12">Cantor et al., 2001</xref>; <xref ref-type="bibr" rid="bib18">Charles Richard et al., 2016</xref>; <xref ref-type="bibr" rid="bib26">Ferretti et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Fortini et al., 2003</xref>; <xref ref-type="bibr" rid="bib28">Fousteri and Mullenders, 2008</xref>; <xref ref-type="bibr" rid="bib38">Jaafar et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Johnson et al., 1999</xref>; <xref ref-type="bibr" rid="bib45">Kunkel and Erie, 2005</xref>; <xref ref-type="bibr" rid="bib57">Liu and Kong, 2021</xref>; <xref ref-type="bibr" rid="bib52">Li and Jin, 2012</xref>; <xref ref-type="bibr" rid="bib50">Li et al., 2009a</xref>; <xref ref-type="bibr" rid="bib58">Lou et al., 2017</xref>; <xref ref-type="bibr" rid="bib60">Lu et al., 2007</xref>; <xref ref-type="bibr" rid="bib62">Mazin et al., 2010</xref>; <xref ref-type="bibr" rid="bib64">McVey et al., 2016</xref>; <xref ref-type="bibr" rid="bib68">Nijman et al., 2005</xref>; <xref ref-type="bibr" rid="bib69">Niraj et al., 2019</xref>; <xref ref-type="bibr" rid="bib71">Overmeer et al., 2010</xref>; <xref ref-type="bibr" rid="bib73">Parsons et al., 2009</xref>; <xref ref-type="bibr" rid="bib74">Pascucci et al., 2018</xref>; <xref ref-type="bibr" rid="bib77">Piwko et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Poletto et al., 2014</xref>; <xref ref-type="bibr" rid="bib79">Poulsen et al., 2013</xref>; <xref ref-type="bibr" rid="bib80">Prasad et al., 2000</xref>; <xref ref-type="bibr" rid="bib81">Rajendra et al., 2014</xref>; <xref ref-type="bibr" rid="bib87">Satoh and Hanawalt, 1996</xref>; <xref ref-type="bibr" rid="bib95">Smirnova et al., 2005</xref>; <xref ref-type="bibr" rid="bib103">Tellier and Chalmers, 2019</xref>; <xref ref-type="bibr" rid="bib112">Westermark et al., 2003</xref>; <xref ref-type="bibr" rid="bib113">Xu et al., 2008</xref>; <xref ref-type="bibr" rid="bib116">Yard et al., 2016</xref>). (<bold>C</bold>) GSEA for terms related to protein stability and endoplasmic reticulum (ER) load performed on DE genes detected in each comparison. For each GO term, enrichments in terms of count and p-value are reported. (<bold>D</bold>) NES (normalized enrichment score) and -log<sub>10</sub> pval for the log<sub>2</sub>FC rank-based GSEA enrichment of the GO term PERK-mediated unfolded protein response (UPR) in treated vs control comparisons. (<bold>E</bold>) GSEA enrichment plot for the PERK-mediated UPR pathway obtained from log<sub>2</sub>FC rank in the M 6 hr vs control comparison in BxPC-3 cells. The expression of leading edge genes is also shown, where key DE genes of the mentioned pathway are reported. (<bold>F</bold>) Boxplots showing the expression level of <italic>ATF4</italic>, <italic>DDIT3,</italic> and <italic>PPP1R15A</italic> (vst-transformed normalized counts) in BxPC-3 cells (n=3).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>DNA repair and proteostasis are key modulators of the response to 3-chloropiperidines (3-CePs)—supporting data.</title><p>(<bold>A</bold>) Expression level of differential expression (DE) genes included in the load of the gene ontology (GO) term regulation of response to DNA damage stimulus (HCT-15 cells, p&lt;0.05) in BxPC-3 and HCT-15 cells. (<bold>B</bold>) Expression level of DE genes included in the load of the GO term proteasomal protein catabolic process (HCT-15 cells, p&lt;0.05) in BxPC-3 and HCT-15 cells. (<bold>C</bold>) Gene set enrichment analysis (GSEA) for terms related to lipid metabolism performed on DE genes detected in each of the considered treated vs control comparisons. For each GO term (p&lt;0.05), enrichments in terms of count and p-value are reported. (<bold>D</bold>) GSEA enrichment plots for the DNA repair pathway obtained from log<sub>2</sub>FC ranks for each of the considered treated vs control comparisons. Key DE genes from the leading edge are reported, together with the expression of SCD in HCT-15 cells (normalized vst-transformed batch corrected counts, n=3).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig3-figsupp1-v1.tif"/></fig></fig-group><p>The more efficient activation of DNA repair in HCT-15 was further confirmed on the overall rank of genes by GSEA at 6 hr of treatment (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). As anticipated, most of the DE genes leading the enrichment in HCT-15 belonged to NER (e.g. <italic>GTF2H3</italic> and <italic>RBX1</italic>) and other recombinational pathways such as homologous repair (HR) (e.g. <italic>MMS22L</italic> and <italic>BARD1</italic>) and fanconi anemia (FA) (e.g. <italic>BRIP1</italic> and <italic>FANCM</italic>), all better suited for the efficient repair of bulky lesions and highly toxic DSBs and crosslinks (<xref ref-type="bibr" rid="bib12">Cantor et al., 2001</xref>; <xref ref-type="bibr" rid="bib52">Li and Jin, 2012</xref>; <xref ref-type="bibr" rid="bib69">Niraj et al., 2019</xref>; <xref ref-type="bibr" rid="bib77">Piwko et al., 2016</xref>; <xref ref-type="bibr" rid="bib87">Satoh and Hanawalt, 1996</xref>; <xref ref-type="bibr" rid="bib112">Westermark et al., 2003</xref>). On the other hand, DE genes in BxPC-3 cells were mostly related to BER (e.g. <italic>APEX1</italic> and <italic>UNG</italic>) and MMR (mismatch repair) (e.g. <italic>MSH6</italic> and <italic>EXO1</italic>), which contribute to the repair of smaller lesions and mismatches (<xref ref-type="bibr" rid="bib27">Fortini et al., 2003</xref>; <xref ref-type="bibr" rid="bib45">Kunkel and Erie, 2005</xref>).</p><p>In the analysis, proteostasis was identified as a second key biological process strictly related to genotoxic stress (<xref ref-type="bibr" rid="bib32">González-Quiroz et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Hutt and Balch, 2010</xref>). HCT-15 cells engaged the protein folding and catabolism apparatus in response to 3-CePs, especially to <bold>B</bold> already at the early time point (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). As observed for DNA repair, DE genes contributing to protein catabolism were upregulated as early as 6 hr of exposure in HCT-15 cells, whereas they were downregulated at the same time point in BxPC-3 and only upregulated after 12 hr (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). This response involved chaperones and co-chaperones (e.g. <italic>HSPA8</italic>, <italic>HSPA1B</italic>, <italic>BAG2</italic>, and <italic>BAG5</italic>), other genes mediating protein catabolism (e.g. <italic>LAMP2</italic> and <italic>CUL3</italic>), and ER morphogenesis (e.g. <italic>RTN4</italic>) (<xref ref-type="bibr" rid="bib24">Eskelinen, 2006</xref>; <xref ref-type="bibr" rid="bib40">Jozsef et al., 2014</xref>; <xref ref-type="bibr" rid="bib83">Ran et al., 2007</xref>; <xref ref-type="bibr" rid="bib91">Scott et al., 2016</xref>). Interestingly, a transcriptional pattern revealed by GSEA at 6 hr of treatment highlighted an intense positive modulation of the PERK-mediated branch of the unfolded protein response (UPR) specifically in BxPC-3 (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>). Even more enlightening were the DE genes leading the enrichment: <italic>ATF4</italic>, <italic>DDIT3</italic> (CHOP), and <italic>PPP1R15A</italic> (GADD34) were significantly upregulated after 6 hr of exposure only in this cell line (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). These genes participate in the PERK-mediated UPR triggering cell death after prolonged ER stress through the aberrant recovery of translation, which induces proteotoxicity (<xref ref-type="bibr" rid="bib34">Han et al., 2013</xref>; <xref ref-type="bibr" rid="bib109">Urra et al., 2013</xref>). This mechanism would reasonably explain the ribosome biogenesis signature observed in BxPC-3 cells. Consistently, recent work reported a particular susceptibility for pancreatic cancer adenocarcinoma to ER stress and protein dyshomeostasis (<xref ref-type="bibr" rid="bib30">Garcia-Carbonero et al., 2018</xref>).</p><p>Furthermore, the ability of HCT-15 cells to control proteostasis may also depend on the activation of lipid and cholesterol biosynthesis in response to the compounds (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C, D</xref>). In fact, among other known pro-survival functions, these pathways contribute to resolving ER stress through pathways involving, e.g., the Stearoyl-CoA Desaturase (<italic>SCD</italic>) enzyme, for which we detected a significant upregulation of the respective transcript in HCT-15 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>; <xref ref-type="bibr" rid="bib85">Romero et al., 2018</xref>; <xref ref-type="bibr" rid="bib101">Tadros et al., 2017</xref>).</p><p>Overall, the transcriptome analysis of this in vitro perturbation experiment allowed us to dissect the different responses to 3-CePs in our model cell lines, pointing toward protein homeostasis and DDR imbalances as mechanisms responsible for the high susceptibility of BxPC-3 cells.</p></sec><sec id="s2-4"><title>The response to 3-CePs is further regulated at the chromatin level</title><p>The transcriptome analysis unveiled a defined framework of responses tuning the sensitivity to 3-CePs. To further characterize them at the epigenetic level, we examined chromatin accessibility in nuclei of BxPC-3 and HCT-15 cells treated with <bold>M</bold> and <bold>B</bold> for 6 hr and 12 hr (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) by ATAC-seq.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The response to 3-chloropiperidines (3-CePs) is further regulated at the chromatin level.</title><p>(<bold>A</bold>) An overview of the applied workflow for the ATAC-seq analysis. (<bold>B</bold>) Number of up- (red) and down-regulated (blue) differentially accessible regions (DARs) in BxPC-3 and HCT-15 cells after treatment with M (10 nM), B (200 nM), or DMSO 0.5% (ctrl) for 6 hr and 12 hr (p-value threshold = 0.05, shrinkage = TRUE). Light blue/red = all detected DARs, dark blue/red = protein coding DARs mapping in promoter regions. (<bold>C</bold>) Accessibility level of cell-specific 6 hr DARs across test conditions. Gene set enrichment analysis (GSEA) was performed on genes associated with DARs with similar regulation, grouped in modules identified by hierarchical clustering: for each cluster, representative gene ontology (GO) terms and genes of the associated load are reported. (<bold>D</bold>) Pairwise integration: ratio-ratio plots report the RNA- and ATAC-seq log<sub>2</sub>FCs of genes showing the same direction of transcriptional and chromatin accessibility regulation and their GSEA. Integration was performed not only at the same time point of 6 hr in both omic layers. For each GO term (p&lt;0.05), enrichments in terms of count and p-value are reported.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The response to 3-chloropiperidines (3-CePs) is further regulated at the chromatin level—supporting data.</title><p>(<bold>A</bold>) Scheme of the applied workflow for the ATAC-seq analyses. (<bold>B</bold>) Principal component analysis (PCA) of ATAC-seq data: PC1 vs PC2 showed samples separation by cell line and PC2 vs PC3 (cell lines depicted separately) showed treatment and time point separation. (<bold>C</bold>) Upset plots reporting up- and down-regulated differentially accessible regions (DARs) (p&lt;0.05) and their overlap between all treated and control comparisons in both cell lines. (<bold>D</bold>) Accessibility level of cell-specific 12 hr DARs across test conditions. Gene set enrichment analysis (GSEA) was performed on genes associated with DARs with similar regulation, grouped in modules identified by hierarchical clustering: for each cluster, representative gene ontology (GO) terms and genes of the associated load are reported.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>The response to 3-chloropiperidines (3-CePs) is further regulated at the chromatin level—supporting data 2.</title><p>(<bold>A</bold>) Pairwise integration: ratio-ratio plots report the RNA- and ATAC-seq log<sub>2</sub>FCs of genes showing the same direction of transcriptional and chromatin accessibility regulation. Integration was performed not at the same time point of 6 hr in both omic layers for compound B. Associated key gene set enrichment analysis (GSEA) terms with p&lt;0.05 are also reported. (<bold>B</bold>) Pairwise integration performed at the same time point of 12 hr in both omic layers in response to M and B. Associated key GSEA terms with p&lt;0.05 are also reported. (<bold>C</bold>) The integration was also performed between chromatin changes at 6 hr and transcriptional responses at 12 hr. Associated key GSEA terms with p&lt;0.05 are also reported.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig4-figsupp2-v1.tif"/></fig></fig-group><p>3-CePs induced evident epigenetic changes in both cell lines, as suggested by PCA (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>) and confirmed by the number of differentially accessible regions (DARs) identified especially in BxPC-3 cells (p&lt;0.05, <xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). For further downstream analyses, we focused on DARs mapping to promoters, whose specific condensation or compaction contribute to modulation of transcription of associated genes (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><p>Also in this case, to better describe the timing of chromatin remodeling, cell-specific promoter-associated DARs elicited after 6 hr and 12 hr of treatment were grouped in clusters sharing a similar pattern of regulation and functional enrichment was performed on the associated genes (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>).</p><p>In BxPC-3 cells, we observed condensation of promoters involved in protein catabolism and DNA damage detection after 6 hr of exposure (Cluster 1 and 2, <xref ref-type="fig" rid="fig4">Figure 4C</xref>), most likely contributing to the transcriptional downregulation of such processes observed at the same time point and in line with the reported improper detection of DNA lesions (<xref ref-type="bibr" rid="bib83">Ran et al., 2007</xref>; <xref ref-type="bibr" rid="bib119">Zhou et al., 2017</xref>). On the contrary, relaxation of peaks involved in apoptosis and redox regulation was detected, in line with evidence from RNA-seq (Cluster 5, <xref ref-type="fig" rid="fig4">Figure 4C</xref>). In HCT-15 cells, relaxation of promoters involved in the DDR as well as protein catabolism (Cluster 9 and 10, <xref ref-type="fig" rid="fig4">Figure 4C</xref>) was observed, again supporting our observations on transcriptome level. Accordingly, we also evidenced a cluster of downregulated promoters involved in rRNA transcription (Cluster 6, <xref ref-type="fig" rid="fig4">Figure 4C</xref>). Altogether, these results attested that the regulation of elicited transcriptional pathways was accommodated by changes at the chromatin level, adding new information on the possible mechanisms determining the cellular responses to 3-CePs.</p><p>A critical step in the analysis of multi-omic datasets is the integration of information obtained from the different layers. Though valuable strategies have been developed in recent years to integrate RNA- and ATAC-seq data, alternatives are still required to optimize and enlarge the functional information obtained from the combination of these powerful techniques (<xref ref-type="bibr" rid="bib1">Ackermann et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Höllbacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib114">Yan et al., 2020</xref>). In this study, we approached data integration through two alternative strategies, that we called pairwise and crosswise.</p><p>As a first level of integration, we identified genes with concordant regulation in RNA- and ATAC-seq upon treatment. In this pairwise integration, we compared the direction of transcriptional regulation of genes to the accessibility of their promoters, as specified in the Methods section and shown in <xref ref-type="fig" rid="fig4">Figure 4D</xref> (<bold>M</bold> 6 hr), <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref> (<bold>B</bold> 6 hr), and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref> (12 hr). Given the biological delay that could exist between chromatin remodeling and a detectable variation in transcript level, pairwise comparisons were also considered between chromatin changes after 6 hr and transcriptional responses after 12 hr of treatment (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). We then applied GSEA to the identified groups of genes across all conditions to point out functional processes of interest.</p><p>Overall, the integration efficiently identified key regulators of previously described processes, once more highlighting the value of applying multi-omics to gain a higher resolution and robustness in the analysis of drug responses. As described in <xref ref-type="fig" rid="fig4">Figure 4D</xref> for compound <bold>M</bold>, and similarly for <bold>B</bold> (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>), we observed coherent upregulation of genes involved in ribosome biogenesis (e.g. <italic>RNPS1</italic>), apoptosis (e.g. <italic>AEN</italic>), BER (e.g. <italic>APEX1</italic>), and cell cycle regulation (e.g. <italic>CDC45</italic>) at 6 hr of treatment in BxPC-3 cells. Meanwhile, at the same conditions, genes regulating the DDR (e.g. <italic>MDM2</italic>), proteostasis, and redox balance (e.g. <italic>GPX1</italic>) were found to be downregulated consistently in both omic layers.</p><p>Instead, the last mentioned processes were activated in HCT-15 cells, as anticipated from previous findings. Indeed, the integration highlighted double-regulated modulators of protein catabolism (e.g. <italic>PSMA3</italic>), DNA repair (e.g. <italic>DTL</italic>), and lipid metabolism, such as the previously described <italic>SCD</italic>. Interestingly, these cells also turned out to activate TGF β signaling (e.g. <italic>BMPR1A</italic>), an important player in cancer drug resistance, in response to <bold>B</bold> (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>; <xref ref-type="bibr" rid="bib8">Brunen et al., 2013</xref>). Furthermore, BxPC-3 cells downregulated, early after 6 hr, genes involved in actin remodeling, a mechanism affecting morphology and function of cancer cells (e.g. <italic>CARMIL1</italic>) (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>; <xref ref-type="bibr" rid="bib13">Caridi et al., 2019</xref>; <xref ref-type="bibr" rid="bib102">Tafazzoli-Shadpour et al., 2020</xref>). Additional insights on double regulation of further processes were evidenced at 12 hr (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>), suggesting for instance autophagy (e.g. <italic>CALCOCO2</italic>) as a putative pathway accounting for the enhanced catabolism in HCT-15 cells (<xref ref-type="bibr" rid="bib17">Chang and Zou, 2020</xref>).</p><p>Collectively, pairwise integration of RNA- and ATAC-seq shed light on genes with robust regulation at the transcriptional and chromatin level, adding further details to the previously identified response pathways.</p></sec><sec id="s2-5"><title>Crosswise integration expedites the comprehension of multi-omic data</title><p>Through the pairwise approach, we identified genes with both transcriptional and chromatin regulation which significantly contributed to the observed cellular response. We further evaluated the crosstalk between RNA- and ATAC-seq at a different level by focusing on groups of genes co-regulated in the two omic layers. The identification of genes sharing similar regulation across conditions either at the transcriptional or chromatin level would maximize the detection of interacting pathways and regulatory processes, e.g., as a result of chromatin changes in promoters tuning the transcription of a certain gene set. This approach, which we termed crosswise integration, was achieved by a combination of horizontal and vertical construction of co-expression network analysis (hCoCena and vCoCena).</p><p>Both algorithms are based on CoCena, which inspects the pattern of gene regulation across conditions in a single transcriptome dataset. Its evolution hCoCena can inspect gene regulatory patterns across omic datasets of the same type and integrate them in a single network (<xref ref-type="bibr" rid="bib3">Aschenbrenner et al., 2021</xref>). Instead, vCoCena was designed to define modules of genes and/or genomic markers, such as DARs, with a similar pattern of regulation across the same conditions in different types of omic data, acting as a multi-omics integration approach.</p><p>As a first step, we created separate co-expression networks for the RNA- and ATAC-seq layers (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). For each of the omic layers, to prevent the construction of a network mostly describing the difference between the two cell lines, we first created independent networks for BxPC-3 and HCT-15 cells. We then integrated the cell-type specific networks separately for transcriptome and chromatin accessibility using hCoCena (RNA-seq BxPC-3 with RNA-seq HCT-15; ATAC-seq BxPC-3 with ATAC-seq HCT-15) (<xref ref-type="bibr" rid="bib3">Aschenbrenner et al., 2021</xref>). The union of the top 1000 most variable DE and top 1000 variable promoter DAR-associated genes detected in treated conditions was selected as input for constructing individual networks (overall 1919 input genes). Clustering of the resulting RNA- and ATAC-seq networks identified a relevant number of gene modules with highly specific regulatory patterns (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B and C</xref>). At this point, the vertical, inter-omic integration (vCoCena) was applied to construct the final network consolidating the information from transcriptome and chromatin accessibility (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>, see Methods for details). The new overall network was then reclustered resulting in integrated modules of co-regulation including nodes originally derived from the two separate layers in different ratios, as shown in <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Crosswise integration expedites the comprehension of multi-omic data.</title><p>(<bold>A</bold>) Overview of the applied workflow for the crosswise integration analysis. (<bold>B</bold>) Integrated modules of genes from the RNA- and ATAC-seq layers obtained with vertical construction of co-expression network analysis (vCoCena) and associated group fold change (GFC) pattern of regulation across conditions. The relative contribution of hits from the RNA- or ATAC-seq layers is also reported for each module. (<bold>C</bold>) Representative gene ontology (GO) terms (p&lt;0.05) for the most relevant modules of genes, identified by gene set enrichment analysis (GSEA). Enrichments in terms of count and p-value are reported. (<bold>D</bold>) Expression and chromatin accessibility levels in HCT-15 cells of genes included in the <italic>steelblue</italic> module (nodes can come from the RNA- or ATAC-seq layer). (<bold>E</bold>) Most representative GO terms from GSEA on genes of the <italic>steelblue</italic> module (key areas: EMT (Epithelial-Mesenchymal Transition), protein catabolism, TGF β signaling, and DNA repair). For each GO term (p&lt;0.05), enrichments in terms of count and p-value are reported.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Crosswise integration expedites the comprehension of multi-omic data—supporting data.</title><p>(<bold>A</bold>) Scheme of the applied workflow for the crosswise integration analysis. (<bold>B</bold>) Horizontally integrated modules of genes from the RNA-seq layer and associated group fold change (GFC) pattern of regulation across conditions. (<bold>C</bold>) Horizontally integrated modules of genes from the ATAC-seq layer and associated GFC pattern of regulation across conditions. (<bold>D</bold>) Crosswise integrated vertical construction of co-expression network analysis (vCoCena) network. (<bold>E</bold>) Most representative gene ontology (GO) terms from gene set enrichment analysis (GSEA) on genes of the maroon, orchid, dark orange, dark grey, indian red, pink, and dark green modules. For each GO term (p&lt;0.05), enrichments in terms of count and p-value are reported. (<bold>F</bold>) Boxplots showing the expression level of <italic>AUNIP</italic> and <italic>KBTBD8</italic> (vst-transformed normalized counts, batch corrected in RNA-seq, n=3) in BxPC-3 and HCT-15 cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig5-figsupp1-v1.tif"/></fig></fig-group><p>The approach combined genes sharing similar regulation in the respective omic dataset, as approximated by the group fold-change (GFC) pattern, with the postulate that genes grouped together cooperate in specific cellular processes. To define the underlying mechanisms, GO enrichment was performed on genes included in each of the modules, and representative biological terms for the most relevant clusters were reported in <xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>. Some modules validated the information obtained through previous analyses (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>): both the orchid and light blue clusters suggested macroautophagy as a putative pathway accounting for the enhanced catabolism observed in HCT-15 cells (<xref ref-type="bibr" rid="bib17">Chang and Zou, 2020</xref>). Consistently, the former RNA-seq-based module was downregulated at 6 hr in BxPC-3 but upregulated already after 6 hr with <bold>B</bold> in HCT-15, while the latter ATAC-seq-based module included peaks condensing after 6 hr only in BxPC-3, confirming the latter cell line as refractory to a rapid engagement of its protein catabolism apparatus. Another mostly RNA-seq-based module validating our previous approach was the maroon module, upregulated after 6 hr in BxPC-3, containing genes involved in ribosome biogenesis, BER, and apoptosis. Furthermore, the dark green and dark gray ATAC modules, downregulated in BxPC-3 cells, include genes modulating redox metabolism and ER stress.</p><p>Other modules offered instead a new perspective on the reactions of the two cell lines: the dark orange RNA module includes genes downregulated in HCT-15 cells at 6 hr but upregulated in BxPC-3 responding to <bold>M</bold>. Interestingly, these hits belong to the Wnt signaling pathway, well-known for regulating ribosome biogenesis and cell growth, adding further information on our initial findings. In addition, the indian red module, upregulated in HCT-15 cells, points toward the tumorigenic JAK-STAT as an additional pathway modulating drug resistance (<xref ref-type="bibr" rid="bib7">Brooks and Putoczki, 2020</xref>).</p><p>The crosswise integration also identified additional regulation, exemplified by the steelblue module. As approximated by the associated GFCs pattern, its 174 genes are positively modulated in HCT-15 cells especially after 6 hr of treatment (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Interestingly, functional enrichment identified hits both from RNA- and ATAC-seq involved in the tumorigenic epithelial-mesenchymal transition (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), a mechanism regulating morphology and invasiveness of cancer cells (e.g. <italic>KBTBD8</italic>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>, from the RNA-seq layer) (<xref ref-type="bibr" rid="bib6">Brabletz et al., 2018</xref>). Other module genes belonged to TGF β signaling (e.g. <italic>FURIN</italic> and <italic>CREB1</italic>; <xref ref-type="fig" rid="fig5">Figure 5E</xref>), a pathway identified already from the pairwise approach and involved in cancer drug resistance (<xref ref-type="bibr" rid="bib8">Brunen et al., 2013</xref>). In addition, the module included genes of recombinational DNA repair belonging to both omic layers, which is in line with our initial findings (e.g. <italic>AUNIP</italic>; <xref ref-type="fig" rid="fig5">Figure 5E</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>).</p><p>Overall, the crosswise integration of RNA- and ATAC-seq data allowed an efficient combination of the functional information from the two omics layers. Clearly, the whole integration added further biology to what we had identified when analyzing transcriptional and chromatin landscape regulation individually.</p></sec><sec id="s2-6"><title>Perturbation-informed basal signatures efficiently predict sensitivity to candidate drugs</title><p>The information derived from the crosswise integration was employed to construct a signature of sensitivity to 3-CePs. Being more potent, <bold>M</bold> was selected as reference to describe a sensitivity prediction framework based on the use of a perturbation-informed omic signature (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>, Methods).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Perturbation-informed basal signatures efficiently predict sensitivity to our candidate drugs.</title><p>(<bold>A</bold>) Overview of the applied workflow for the sensitivity signature construction and associated drug susceptibility prediction. (<bold>B</bold>) M sensitivity signature genes (red = signature up and blue = signature down) pinpointed from all differential expression (DE) genes in the BxPC-3 vs HCT-15 baseline comparison. (<bold>C</bold>) Pearson correlation between predicted sensitivity score and viability decrease in a subset of human protein atlas (HPA) (cell atlas) cell lines (validation set). (<bold>D</bold>) Sensitivity scores predicted from gene set variation analysis (GSVA) enrichment of our up and down signatures in RNA-seq profiles of TCGA tumor samples. Median values for all sample scores and within each tumor type are reported. (<bold>E</bold>) Overview of the applied workflow for the LASSO-based ML setup. (<bold>F</bold>) Predictive outcome of the trained model (Pearson correlation R and RMSE (root-mean-square error) are reported). (<bold>G</bold>) Pearson correlation between predicted cisplatin sensitivity score and IC<sub>50</sub> in a subset of HPA (cell atlas) cell lines (validation set). (<bold>H</bold>) Cisplatin sensitivity scores predicted from GSVA enrichment of our up and down signatures in RNA-seq profiles of TCGA tumor samples. Median values for all sample scores and within each tumor type are reported.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Perturbation-informed basal signatures efficiently predict sensitivity to our candidate drugs—supporting data.</title><p>(<bold>A</bold>) Scheme of the applied workflow for the sensitivity signature construction and associated drug susceptibility prediction. (<bold>B</bold>) Representative gene ontology (GO) terms (p&lt;0.05) for genes of the M sensitivity signature (up and down), identified by gene set enrichment analysis (GSEA). Enrichments in terms of count and p-value are reported. (<bold>C</bold>) Human protein atlas (HPA) (cell atlas) cell lines separation based on gene set variation analysis (GSVA) enrichment of our newly constructed up vs down signatures of sensitivity to M. Color scale reflects samples predicted sensitivity score (up signature enrichment - down signature enrichment). (<bold>D</bold>) Pearson correlation between predicted sensitivity score and viability decrease in a subset of HPA (cell atlas) cell lines (validation set) using a random signature. (<bold>E</bold>) Pearson correlation between predicted sensitivity score and viability decrease in a subset of HPA (cell atlas) cell lines (validation set) using a control signature composed by differential expression (DE) genes with top up and down log<sub>2</sub>FC. (<bold>F</bold>) Predictive performance after the exclusion of genes belonging to our signature from training and test set transcriptomes (Pearson correlation R and RMSE are reported).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Validation analysis on cisplatin sensitivity confirms the versatility of the pipeline.</title><p>(<bold>A</bold>) Predicting performance of our model on tumor-specific subtypes (Pearson’s correlation and RMSE are reported). (<bold>B</bold>) RNA-seq principal component analysis (PCA) (PCs 1 vs 2 and 2 vs 3) for the cisplatin dataset. (<bold>C</bold>) ATAC-seq PCA (PCs 1 vs 2 and 2 vs 3) for the cisplatin dataset. (<bold>D</bold>) Identified number of differential expression (DE) and differentially accessible regions (DARs) in all comparisons for the cisplatin datasets using parameters described in Methods section. (<bold>E</bold>) Crosswise integrated cisplatin vertical construction of co-expression network analysis (vCoCena) network.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-fig6-figsupp2-v1.tif"/></fig></fig-group><p>First, we selected vCoCena clusters based on the highest difference in regulation between the two cell lines after treatment with <bold>M</bold>, considering only the most informative time point of 6 hr (selected modules: maroon, dark green, steelblue, indian red, light green, pink, sandy brown; module selection criteria are described in detail in the Methods section). According to our hypothesis, genes that belong to these modules, coming both from RNA- and ATAC-seq analyses, are expected to be the major determinants of the differential susceptibility in the two cell lines.</p><p>Importantly, we postulated that features accounting for sensitivity should be intrinsic for the two cell lines, thus explained already by significant differences in their basal status. For this reason, we performed DE analysis between untreated BxPC-3 and HCT-15 control groups, identifying genes up- and down-regulated at the transcriptional level in the high-sensitive cell line (p&lt;0.01, IHW correction, abs[log<sub>2</sub>FC]&gt;1), and sorted out only those belonging to previously selected modules. This approach resulted in a subgroup of genes with different basal expression in BxPC-3 cells as well as a sufficiently compound- and cell line-specific regulation upon perturbation. This perturbation-informed signature was composed of 307 genes upregulated (signature up) and 123 genes downregulated (signature down) in the high-sensitive BxPC-3 cells (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, gene list available in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). GO enrichment on these genes identified protein synthesis, folding and catabolism, lipid metabolism, matrix organization, and actin remodeling among the most significant biological functions (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Some interesting genes in the up signature were <italic>BNIP3</italic>, proapoptotic, <italic>SCD</italic>, the already discussed regulator of lipid metabolism and SLFN11, involved in DDR and known response biomarker (<xref ref-type="bibr" rid="bib120">Zoppoli et al., 2012</xref>). Among those composing the down signature, we identified <italic>YOD1</italic>, <italic>HERPUD1</italic>, and <italic>HSPA5</italic>, involved in protein homeostasis and ER stress, but also <italic>ERCC6</italic> and <italic>AUNIP</italic> of the DDR (<xref ref-type="fig" rid="fig6">Figure 6B</xref>; <xref ref-type="bibr" rid="bib23">Ernst et al., 2009</xref>; <xref ref-type="bibr" rid="bib58">Lou et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Pascucci et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Schulze et al., 2005</xref>).</p><p>To determine the robustness of the obtained signature and its ability to predict sensitivity to <bold>M</bold>, we next performed a gene set variation analysis (GSVA) on publicly available transcriptomes of common cell lines,(<xref ref-type="bibr" rid="bib107">Uhlén et al., 2015</xref>) testing for both the up and down signatures (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). A sensitivity score was calculated for each cell line as the difference between the enrichment scores (ESs) of the up and the down signatures. The predicted rank was validated experimentally on representative cell lines (A-431, A549, HEK-293, NTERA-2, PC-3, and SH-SY5Y), for which we assessed the residual cell viability after 72 hr treatment with <bold>M</bold> 10 nM (see Methods<italic>,</italic> <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). As shown in <xref ref-type="fig" rid="fig6">Figure 6C</xref>, our perturbation-informed signature demonstrated a strong predictive capacity as attested by the high positive correlation between viability decrease and predicted sensitivity score (Pearson’s R: 0.834, p: 0.0398; <xref ref-type="fig" rid="fig6">Figure 6C</xref>). This signature outperformed a random one containing the same number of genes (R: −0.023, p: 0.97, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>) and also a signature of equal size composed by the top up- and down-regulated genes between the two cell lines (R: 0.33, p: 0.52, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>, gene list available in <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). Collectively, our crosswise integration approach resulted in a perturbation-informed signature capable of predicting drug sensitivity in a wide range of untreated tumor cell lines commonly used in cancer research.</p><p>Encouraged by these results, we adapted our strategy to mimic a clinical setting utilizing the primary tumor samples of the Cancer Genome Atlas TCGA database. By applying GSVA, we examined the relative distribution of samples from different tumor types based on the calculated sensitivity score, unveiling which cancer types were predicted as generally more susceptible (i.e. kidney renal clear cell carcinoma [KIRC], PAAD, glioblastoma multiforme [GBM], and kidney renal papillary cell carcinoma [KIRP]) or less sensitive (i.e. rectum adenocarcinoma, colon adenocarcinoma [COAD], uterine corpus endometrial carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma) to <bold>M</bold>, providing a framework for further in vivo development of this compound (<xref ref-type="fig" rid="fig6">Figure 6D</xref>).</p><p>Interestingly, the predicted tumor type with the highest sensitivity turned out to be KIRC, demonstrating that the designed signature was not driven by the original cell type of the cell lines used for its extrapolation and could go beyond the original cancer type. At the same time, PAAD and COAD (as BxPC-3 and HCT-15 cells) were still among the most and least sensitive, confirming that cell type intrinsic determinants of susceptibility exist and are represented in our signature. Interestingly, intra-tumor variability resulted in a continuous distribution of samples scores within each cancer group, confirming the importance of clinically translating such predictions beyond the tumor type to better address patient-specific therapeutic needs.</p><p>To enlarge the accessibility and clinical translatability of our framework, we finally introduced a LASSO regression model to predict the sensitivity of tumor samples in the external reference dataset (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). We trained a regression model using TCGA basal transcriptomic profiles labeled with the previously predicted sensitivity scores in order to create a self-supervised system able to emulate the prediction irrespective of the context dataset, detaching the predictive tool from the data space. From a clinical perspective, this further step would allow one to collect a patient basal transcriptome and feed it to the model, not only improving the performance of the prediction but also avoiding any issue related to data sharing since the model itself does not contain any patients’ sensitive data.</p><p>In detail, TCGA samples were labeled according to the calculated continuous sensitivity scores. Next, the model was trained on 80% of the data and tested on the remaining 20%, which efficiently predicted drug sensitivity within the test samples (R: 0.97, RMSE: 0.069) (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Notably, such predictive capacity was maintained even when excluding from the transcriptomes all the signature genes used to define the sensitivity score label of the samples, suggesting the biological robustness of the predictive system (R: 0.97, RMSE: 0.072; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>). In fact, while the signature itself was good enough to rank samples based on experimental biological evidence, the model went beyond the initial signature by relying on additional predictive features previously not identified. Moreover, the classifier performed well also on separate cancer types, demonstrating its capacity to address intra-tumor type heterogeneity (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A</xref>).</p><p>As a last validation step to confirm the versatility of our approach, we applied the pipeline to the prediction of cancer cell lines’ sensitivity to cisplatin, a thoroughly reported broad-acting chemotherapeutic introduced as a DNA damaging agent (<xref ref-type="bibr" rid="bib43">Kelland, 2007</xref>). We applied the same analysis pipeline as outlined for the 3-CePs. First, we selected Jurkat and BxPC-3 cells as high- and low-sensitive cancer cell lines based on the IC<sub>50</sub>s reported in the Genomics of Drug Sensitivity in Cancer database (Jurkat: 3 µM, BxPC-3: 55 µM) (<xref ref-type="bibr" rid="bib115">Yang et al., 2013</xref>). Then, we acquired RNA- and ATAC-seq profiles after 6 hr of 3 µM cisplatin treatment in both cell lines. Next, we processed data as reported for 3-CePs (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2B</xref>, C, D), up to the construction of an integrated vCoCena network (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2E</xref>). At this point, we built the perturbation-based sensitivity signature specific for cisplatin. Due to the higher number of DE genes between the cell lines using previous parameters, we applied a higher logFC threshold in the call between the untreated controls (p&lt;0.01, IHW correction, abs[logFC]&gt;2.5). In this way, we obtained an overall signature comparable in size to the <bold>M</bold> one (signature up: 107, signature down: 363, see Methods for details, <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>). The signature was then tested on Human Cell Atlas (HCA) transcriptomes, subsetting for cancer cell lines whose IC<sub>50</sub> was available in the Genomics of Drug Sensitivity in Cancer database (<xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>). Results confirmed the applicability of our approach, which predicted sensitivity to this reference drug with high accuracy, showing a strong anticorrelation between predicted sensitivity score and actual IC<sub>50</sub> (Pearsons’s R: −0.76, p: 0.007, <xref ref-type="fig" rid="fig6">Figure 6G</xref>). Even more promising, despite the fact that our model was not trained on data derived from testicular cancer, the prediction on TCGA tumor transcriptomes highlighted testicular germ cell tumor TGCT as the most sensitive cancer type (<xref ref-type="fig" rid="fig6">Figure 6H</xref>), a finding that is clinically confirmed being testicular cancer efficiently treated with cisplatin since decades (<xref ref-type="bibr" rid="bib43">Kelland, 2007</xref>).</p><p>Overall, we demonstrated how to further employ the integrated RNA- and ATAC-seq information to assemble an accurate and clinically-accessible predictive strategy capable of orienting drug development and supporting medical practice in the context of precision oncology.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Despite the advances of the last decades, efforts are required to expedite routine use of omic-scale approaches in preclinical and clinical settings. Recent work illustrated the potential for omics technologies to accelerate the process of drug discovery from the initial identification of candidate lead compounds up to their preclinical and clinical development (<xref ref-type="bibr" rid="bib41">Kagohara et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">McFarland et al., 2020</xref>; <xref ref-type="bibr" rid="bib84">Rendeiro et al., 2020</xref>; <xref ref-type="bibr" rid="bib92">Shaheen et al., 2018</xref>; <xref ref-type="bibr" rid="bib97">Srivatsan et al., 2020</xref>; <xref ref-type="bibr" rid="bib117">Ye et al., 2018</xref>). Furthermore, improvements in computational approaches for omics data analyses (<xref ref-type="bibr" rid="bib44">Koromina et al., 2019</xref>; <xref ref-type="bibr" rid="bib55">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Mun et al., 2020</xref>) and an ever-increasing availability of public reference datasets (<xref ref-type="bibr" rid="bib76">Perez-Riverol et al., 2019</xref>) make it now possible to develop completely new pipelines to address the pharmacological profile of any given drug, from its MoA to sensitivity biomarkers (<xref ref-type="bibr" rid="bib22">Dugger et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Matthews et al., 2016</xref>; <xref ref-type="bibr" rid="bib72">Paananen and Fortino, 2020</xref>).</p><p>Here, we combined transcriptome and chromatin accessibility analyses within perturbation experiments to investigate the specific activity profile of 3-CePs, a new class of potential anticancer agents acting as DNA alkylators (<xref ref-type="bibr" rid="bib15">Carraro et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Carraro et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Helbing et al., 2020</xref>; <xref ref-type="bibr" rid="bib96">Sosic et al., 2017</xref>; <xref ref-type="bibr" rid="bib122">Zuravka et al., 2015a</xref>; <xref ref-type="bibr" rid="bib121">Zuravka et al., 2014</xref>; <xref ref-type="bibr" rid="bib123">Zuravka et al., 2015b</xref>). Our analysis unveiled the basis of the preferential activity of 3-CePs against the pancreatic cancer cell line BxPC-3, which was demonstrated to be unable to properly control proteostasis and DDR under stress conditions upon exposure to the alkylating agents. On the contrary, the low-sensitive colorectal adenocarcinoma cell line HCT-15 potentiated protein folding and catabolism all together activating a more efficient DNA repair after treatment. Due to unresolved genotoxic stress and proteostasis dysregulation, widely described as crosstalking events (<xref ref-type="bibr" rid="bib32">González-Quiroz et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Hutt and Balch, 2010</xref>), BxPC-3 cells activated the apoptotic branch of the PERK-mediated UPR via CHOP and GADD34, both upregulated after treatment (<xref ref-type="bibr" rid="bib34">Han et al., 2013</xref>; <xref ref-type="bibr" rid="bib109">Urra et al., 2013</xref>). Accordingly, such behavior is in line with the described sensitivity of pancreatic cancer adenocarcinoma to ER stress and protein dyshomeostasis (<xref ref-type="bibr" rid="bib30">Garcia-Carbonero et al., 2018</xref>).</p><p>Beyond validating the described results, the analysis of chromatin accessibility was first employed to identify genes with concordant transcriptional and epigenetic regulation, a step we called pairwise integration. The approach revealed both epigenetic and transcriptional regulation of key response pathways, identifying apoptotic and ribosome biogenesis mediators upregulated in BxPC-3 and downregulated in HCT-15, as well as redox balance and proteostasis hits upregulated in HCT-15 and downregulated in BxPC-3. In addition, actin dynamics, shown to assist DSBs repair (<xref ref-type="bibr" rid="bib13">Caridi et al., 2019</xref>), were identified to be silenced in the more sensitive cell line.</p><p>To further evaluate the interaction between transcriptional and chromatin accessibility responses, we proposed here a new versatile approach for the crosswise integration of RNA- and ATAC-seq, based on vCoCena. This approach identified modules of genes co-regulated in the two omic layers across the analyzed experimental conditions. Combined with the pairwise integration, this standalone method not only recapitulated the result of the independent transcriptomic and epigenomic analysis, but also highlighted additional pathways, e.g., EMT and TGF β signaling, which modulate the response to the compounds. Indeed, a protumorigenic role was established for TGF β in mediating carcinogenicity linked to epithelial-mesenchymal transition, both processes that could additionally explain the more efficient response of HCT-15 cells to 3-CePs (<xref ref-type="bibr" rid="bib8">Brunen et al., 2013</xref>). Efficient and versatile, this approach represents a valid option to integrate the information from multi-omic studies substituting the separate examination of each omic dataset.</p><p>To further assist the development of 3-CePs, we set up a pilot sensitivity prediction framework readily transferable from the bench to the clinics. We designed a perturbation-informed signature derived from the integrated omic layers filtering the differentially expressed genes between the two cell lines at a steady state for those specifically involved in the cellular response to the treatment. Though based on a limited number of perturbed profiles, this gene signature predicted with high precision the sensitivity to 3-CePs only relying on the untreated transcriptome of test cell lines. Not only did this approach work when applied to our candidate drugs, but it also efficiently predicted sensitivity to the clinically established antineoplastic agent cisplatin. The possibility to improve predictions from basal transcriptomes sounds attractive from a clinical perspective since it overcomes the need to screen for thousands of drugs and collect the same amount of profiles from limitedly-available patient samples, such as biopsies (<xref ref-type="bibr" rid="bib2">Adam et al., 2020</xref>). Applied to TCGA tumor samples, this approach provided a list of susceptible cancer types, e.g., KIRC and PAAD, to support the further development of our drug candidate, and, once transferred on an ML platform, could offer a versatile predictive strategy translatable to the clinics (<xref ref-type="bibr" rid="bib44">Koromina et al., 2019</xref>; <xref ref-type="bibr" rid="bib111">Warnat-Herresthal et al., 2021</xref>).</p><p>In this study, we combined transcriptomic and epigenetic data to guide our exemplary analysis. Nevertheless, the modularity of our framework allows, with only minimal adjustment, its application to other omic technologies or experimental designs. The pipeline showed to be versatile, being applicable to other drugs and, as a consequence, generalizable to other diseases and target cell populations. Indeed, the vCoCena integration, which is instrumental for both the biological interpretation of the data and the definition of the perturbation-informed signature, is agnostic of the type of data used as soon as this is reduced to a network of co-regulation.</p><p>In conclusion, we present a complete end-to-end workflow to implement the use of multi-omics in drug development, providing a human-readable toolbox to interrogate pharmacological questions in both preclinical and clinical settings. We applied this framework to understand the MoA of 3-CePs revealing the cellular determinants of sensitivity to this novel class of drugs and providing additional information for their clinical development as anticancer candidates. Given its versatility, we envision our workflow to be a broadly applicable resource to assist researchers in different steps of the drug discovery and development process.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">HCT-15</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">#CCL-225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">BxPC-3</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">#CRL-1687</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">A549</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">#CRM-CCL-185</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">HEK-293</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">#CRL-1573</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">Jurkat</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">#TIB-152</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">PC-3</td><td align="left" valign="bottom">Others (see Cell lines culturing)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">NTERA-2</td><td align="left" valign="bottom">Others (see Cell lines culturing)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">SH-SY5Y</td><td align="left" valign="bottom">Others (see Cell lines culturing)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">A-431</td><td align="left" valign="bottom">Others (see Cell lines culturing)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-human H2A.X, (mouse monoclonal, clone 2F3)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">#613405</td><td align="char" char="." valign="bottom">(FC = 1:25)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Tn5</td><td align="left" valign="bottom">In-house</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Foxp3 Transcription Factor Staining Buffer Set</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">#00-5523-00</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">miRNeasy mini kit</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TruSeq stranded total RNA kit</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Pico488 dsDNA quantification reagent</td><td align="left" valign="bottom">Lumiprobe</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Propidium Iodide</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">#P4864</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">LIVE/DEAD Near-IR fixable dye</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">M, B</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib14">Carraro et al., 2019</xref>; <xref ref-type="bibr" rid="bib121">Zuravka et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">cisplatin</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">BD</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">bcl2fastq2</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">STAR</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib21">Dobin et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DESeq2</td><td align="left" valign="bottom">Bioconductor</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">clusterProfiler</td><td align="left" valign="bottom">Bioconductor</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Trimmomatic</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib5">Bolger et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">bowtie2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Langmead and Salzberg, 2012</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Picard</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard">http://broadinstitute.github.io/picard</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">deeptools</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib82">Ramírez et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">samtools</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib23">Ernst et al., 2009</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MACS2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib48">Lawrence et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GenomicRanges</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib118">Zhang et al., 2008</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GenomicAlignments</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib118">Zhang et al., 2008</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ChIPseeker</td><td align="left" valign="bottom">Bioconductor</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">hCoCena</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/MarieOestreich/hCoCena">https://github.com/MarieOestreich/hCoCena</ext-link>; <xref ref-type="bibr" rid="bib70">Oestreich, 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">vCoCena</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib29">Friedman et al., 2010</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell lines culturing</title><p>Colon (HCT-15, #CCL-225), pancreatic (BxPC-3, #CRL-1687), lung (A549, #CRM-CCL-185) carcinoma cell lines, human embryonic kidney (HEK-293, #CRL-1573) and acute T cell leukemia cells (Jurkat, #TIB-152) were purchased from ATCC (American Type Culture Collection). Prostate (PC-3) and testis (NTERA-2) carcinoma cell lines were kindly provided by Prof. W. Kolanus (LIMES institute; University of Bonn), neuroblastoma (SH-SY5Y) by Prof. D. Schmucker (LIMES institute; University of Bonn), and epidermoid (A-431) carcinoma by Prof. G. Zunino (Istituto Nazionale dei Tumori di Milano). Cell lines were maintained in logarithmic phase at 37°C in a 5% carbon dioxide atmosphere using RPMI-1640 (for BxPC-3, HCT-15, PC-3, Jurkat), DMEM (for A-431, HEK-293, NTERA-2, SH-SY5Y), or Ham’s F-12K (for A549) media (by Gibco or Euroclone) containing 10% fetal calf serum, antibiotics (50 units/mL penicillin and 50 μg/mL streptomycin) and 2 mM L-glutamine (Euroclone).</p></sec><sec id="s4-2"><title>Direct detection and quantification of early DNA damage</title><p>The extent of early DNA damage induced by 3-CePs in treated cells was assessed by the Fast Micromethod single-strand-break assay. This approach can detect both single and DSBs, as well as alkali-labile adduct sites in the DNA of treated cells. 5000 cells/well were seeded in 96-well microplates and treated next day for 6 hr with <bold>M</bold> (10 nM and 100 nM), <bold>B</bold> (200 nM and 2 µM), or DMSO 0.5%. After treatment, we measured the effect of double and single-strand breaks on the rate of unwinding of cellular DNA in denaturing alkaline conditions by monitoring the fluorescence of a dye that preferentially binds to dsDNA up to 20 min (Pico488 dsDNA quantification reagent, Lumiprobe). The assay was performed following the protocol of <xref ref-type="bibr" rid="bib89">Schröder et al., 2006</xref>. Two experimental replicates were performed, each one including three technical repeats. Fluorescence signal was acquired by the FLUOstar Omega microplate reader using Omega 5.11 software (BMG LABTECH). The resulting curves based on mean normalized fluorescence values obtained for each treatment and the control (DMSO 0.5%) are reported in <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</p></sec><sec id="s4-3"><title>Cell cycle and flow cytometric H2AX phosphorylation analyses</title><p>Possible effects of 3-CePs treatments on the cell cycle distribution of both cell lines were analyzed by FACS, staining cellular DNA with the PI (propidium iodide, Sigma) dye. In addition, we monitored by antibody staining the phosphorylation of histone H2AX, upstream event of the DDR cascade, after 6 hr and 12 hr of treatment in order to investigate the ability of BxPC-3 and HCT-15 cells to detect DSBs. 200,000 cells/well were seeded in 12-well plates and treated next day for 6 hr, 12 hr, or 72 hr with <bold>M</bold> (10 nM), <bold>B</bold> (200 nM), or DMSO 0.5%. Cells were harvested, washed with PBS, fixed, and permeabilized with the Foxp3 transcription factor staining buffer set (eBioscience, cat. #00-5523-00). In detail, cell suspensions were fixed for 1 hr at room temperature with FixBuffer, washed twice with PermBuffer, and stained with anti-human γH2AX AlexaFluor 488 (Biolegend, clone 2F3, cat. #613405) for 1 hr at 4°C. After the first staining, cells were washed first with PermBuffer, then with PBS and stained secondly with PI (30 min, dark). Samples were acquired on a BD Symphony instrument equipped with five lasers (UV, violet, blue, yellow-green, and red), the spectral overlap between the channels were determined with single stained samples using FACSDiva (v 9.1.2). Samples were analyzed in FlowJo (BD, v 10.7.1). Events were gated first according to FSC-A and SSC-A and cleaned from cell doublets with three consecutive gates (FSC-A vs FSC-H; SSC-A vs SSC-H; and PI-A vs PI-H). The frequency of cells within each phase of the cell cycle was calculated using the PI-A signal with the FlowJo built-in algorithm (Watson model with constrained G2 peak). Three biological replicates were obtained per condition and unpaired two-tailed Student’s <italic>t</italic>-test was performed to assess statistical significance (p&lt;0.05).</p></sec><sec id="s4-4"><title>Cells treatments for RNA-seq and ATAC-seq experiments</title><p>For both RNA- and ATAC-seq analyses, 300,000 cells/well were seeded in 6-well plates and treated next day for 6 hr, 12 hr, or 72 hr with <bold>M</bold> (10 nM), <bold>B</bold> (200 nM), cisplatin (3 µM, Sigma), or DMSO 0.5%. Both for RNA- and ATAC-seq samples, three experimental replicates were obtained for each condition in case of 3-CePs datasets, four replicates were instead produced for the cisplatin datasets.</p></sec><sec id="s4-5"><title>RNA-seq experiment</title><p>At the end of the treatment, cells were washed, resuspended in 1 mL QIAzol reagent (Qiagen), and stored at −80°C. We extracted the RNA using the miRNeasy mini kit (Qiagen) and checked the RNA integrity and quantity using the tapestation RNA assay on a tapestation 4200 instrument (both from Agilent). We used 750 ng total RNA to generate NGS libraries using the TruSeq stranded total RNA kit (Illumina) following manufacturer’s instructions. We checked library size distribution via tapestation using D1000 on a tapestation 4200 instrument (Agilent) and quantified the libraries via Qubit HS dsDNA assay (Invitrogen). We clustered the libraries at 250pM final clustering concentration on a NovaSeq6000 instrument using SP and S2 v1 chemistry (Illumina) and sequenced paired-end 2×50 cycles before demultiplexing using bcl2fastq2 v2.20.</p></sec><sec id="s4-6"><title>ATAC-seq experiment</title><p>At the end of the treatment, cells were washed, harvested, resuspended in PBS with 1 mM EDTA, stained with the LIVE/DEAD Near-IR fixable dye (Invitrogen, cat. #10119) for 10 min at 4°C, centrifuged and suspended in PBS with 1 mM EDTA. 20,000 living cells/sample were sorted by FACS and further processed for nuclei isolation and transposition reaction following the protocol of <xref ref-type="bibr" rid="bib9">Buenrostro et al., 2013</xref>. Being the number of dead cells found out to be negligible, sorting before transposition was not applied to samples treated with cisplatin.</p><p>We generated ATAC-libraries from tagmented cells following the protocol of Buenrostro et al. We checked library size distribution via tapestation using D5000 assay (ATAC) on a Tapestation 4200 instrument (both from Agilent) and quantified the libraries via Qubit HS dsDNA assay (Invitrogen). We clustered the libraries at 250pM final clustering concentration on a NovaSeq6000 instrument using SP and S2 v1 chemistry (Illumina) and sequenced paired-end 2×50 cycles before demultiplexing using bcl2fastq2 v2.20.</p></sec><sec id="s4-7"><title>RNA-seq data analysis</title><p>Reads were aligned and quantified with STAR (v 2.5.2 a) (<xref ref-type="bibr" rid="bib21">Dobin et al., 2013</xref>) using standard parameters and mapped against the GRCh38p13 human reference genome (Genome Reference Consortium). Raw counts were imported, prefiltered to exclude low-count genes (3-CePs:&gt;100 reads, 17.693 transcripts; cisplatin:&gt;10 reads, 27.404 transcripts), normalized and VST-transformed (variance stabilizing transformation) following the DESeq2 (Bioconductor, v 1.26.0) pipeline using default parameters (<xref ref-type="bibr" rid="bib31">Gentleman et al., 2004</xref>; <xref ref-type="bibr" rid="bib59">Love et al., 2014</xref>). SVA (surrogate variable analysis) was applied to identify latent variables responsible for batch effects and included in the DESeq2 model (3-CePs: 4 SVs, cisplatin: 3 SVs) (<xref ref-type="bibr" rid="bib49">Leek et al., 2012</xref>). All present transcripts were used as input for PCA. The call for differentially expressed genes was performed for all treated vs control comparisons (separate cell lines) using an adjusted p-value threshold equal to 0.05, where IHW was adopted for multiple testing and shrinkage was applied. Only protein-coding hits were considered for further functional analyses on DE genes. GSEA based on the GO (gene ontology) biological process database was employed for functional enrichments, both based on DE genes (<xref ref-type="supplementary-material" rid="supp1 supp2">Supplementary files 1 and 2</xref>) or log<sub>2</sub>FC-based ranks. All enrichment dotplots report the count and p-value associated with each term, when p&lt;0.05. Representative enrichment terms in <xref ref-type="fig" rid="fig2">Figure 2C</xref> were selected manually from enrichment maps obtained for each group of genes depicted in the dotplot (<xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>): to remove semantic redundancy, only the most significant nodes among those converging into the same hub were reported (higher count and lower p-value, example in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). SVA batch-corrected normalized VST-transformed counts were used as input for boxplots, heatmaps, and log<sub>2</sub>FC-based GSEA. Hierarchical clustering was applied to identify blocks of DE genes with similar regulations across conditions as reported in the presented heatmaps (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). In the same heatmaps, row-scaled expression levels of cell-specific DE genes elicited at 6 hr and 12 hr were reported separately for each of the analyzed conditions.</p></sec><sec id="s4-8"><title>ATAC-seq data analysis</title><p>After adapter trimming using Trimmomatic v 0.36 (<xref ref-type="bibr" rid="bib5">Bolger et al., 2014</xref>), the sequencing reads were aligned bowtie2 v 2.3.5 against the GRCh38p13 human reference genome (<xref ref-type="bibr" rid="bib47">Langmead and Salzberg, 2012</xref>). Subsequently, duplicated reads were removed using Picard <italic>dedup</italic> function, and the transposase-induced offset was corrected using the deeptools v 3.1.3 <italic>alignmentSieve</italic> function (<xref ref-type="bibr" rid="bib82">Ramírez et al., 2014</xref>). After sorting and indexing bam files with samtools v 1.9 (<xref ref-type="bibr" rid="bib51">Li et al., 2009b</xref>), peak calling was performed using MACS2 v 2.1.2 (<xref ref-type="bibr" rid="bib48">Lawrence et al., 2013</xref>). Peak regions from sample-specific peak calling results were unified in R v 3.6.2 using the <italic>reduce</italic> function implemented in the GenomicRanges package v 1.38.0 (<xref ref-type="bibr" rid="bib118">Zhang et al., 2008</xref>) prior to quantification of sequencing reads in these unified peak regions using the <italic>summarizeOverlaps</italic> function implemented in the GenomicAlignments package v 1.22.1 (<xref ref-type="bibr" rid="bib118">Zhang et al., 2008</xref>). Raw counts were prefiltered to exclude low-count peaks (&lt;20 reads, 3-CePs: 63.434 peaks, cisplatin: 170.844 peaks), normalized and VST-transformed following the DESeq2 (Bioconductor, v 1.26.0) pipeline using default parameters (<xref ref-type="bibr" rid="bib31">Gentleman et al., 2004</xref>; <xref ref-type="bibr" rid="bib59">Love et al., 2014</xref>). Peak regions were annotated using <italic>ChIPseeker</italic> (Bioconductor, v1.22.1). All present peaks were used as input for PCA. The call for DARs was performed for all treated vs control comparisons (separate cell lines) considering a p&lt;0.05 threshold. Only peaks mapping in promoters of protein-coding regions (according to ChIPseeker annotation) were considered for further functional analyses. GSEA based on the GO biological process database was employed for functional enrichments based on DAR-associated genes (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Normalized and, where specified, vst-transformed counts were used as input for heatmaps and boxplots. Hierarchical clustering was applied to identify blocks of DAR-associated genes with similar regulations across conditions as reported in the presented heatmaps (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). In the same heatmaps, row-scaled accessibility levels of cell-specific DARs at 6 hr and 12 hr were reported separately for each of the analyzed conditions. Reference promoter peaks in case of multiple mapping to the same gene were chosen based on higher variance. For the pairwise integration between transcriptional and chromatin accessibility data, we identified hits having the same sign of regulation in RNA- and ATAC-seq which were DE (protein-coding) and/or DAR-associated (protein-coding mapping in promoters). Reference peaks in case of multiple mapping to the same gene were chosen based on lower p-value in the specific comparison. Since a delay could exist between a prior chromatin remodeling and a detectable variation in the respective transcript level, pairwise comparisons were considered not only at the same time point in both omic layers but also between chromatin changes at 6 hr and transcriptional responses at 12 hr. Interesting gene names for each of the considered comparisons were also reported, and GSEA enrichment was applied as specified above.</p></sec><sec id="s4-9"><title>Crosswise integration of RNA-seq and ATAC-seq data</title><p>The crosswise integration of transcriptomic and chromatin accessibility data was achieved through an adaptation of the CoCena (construction of co-expression network analysis - automated) tool which inspects the pattern of regulation of genes across conditions in a single transcriptome dataset. The core principles driving both network construction and gene modules detection by CoCena have been described previously (<xref ref-type="bibr" rid="bib3">Aschenbrenner et al., 2021</xref>). In this analysis, we first optimized the design of separate co-expression networks for the RNA- and ATAC-seq layers. To avoid the creation of networks mostly describing cell type differences, we calculated separate networks for BxPC-3 and HCT-15 cells which were then integrated horizontally through hCoCena (<xref ref-type="bibr" rid="bib3">Aschenbrenner et al., 2021</xref>). The union of all top 1000 variable DE and top 1000 variable promoter DAR-associated genes detected in treated conditions was selected as input for constructing all networks. For the construction of cell-specific networks, the specified Pearson correlation cutoffs, edges and nodes for RNA-seq (3-CePs: BxPC-3 cutoff = 0.75, edges = 104002, and nodes = 1711; HCT-15 cutoff = 0.707, edges = 54222, and nodes = 1747; cisplatin: BxPC-3 cutoff = 0.863, edges = 107434, and nodes = 1766; Jurkat: cutoff = 0.955, edges = 21708, and nodes = 1735) and ATAC-seq (3-CePs: BxPC-3 cutoff = 0.693, edges = 7092, and nodes = 1559; HCT-15 cutoff = 0.707, edges = 5431, and nodes = 1510; cisplatin: BxPC-3 cutoff = 0.783, edges = 297385, and nodes = 1685; Jurkat cutoff = 0.876, edges = 6140, and nodes = 1620) were used. The horizontally integrated networks contained the union of all nodes and edges coming from parent networks, where edges between nodes connected in both parent layers were recalculated as a mean of their original weights. Clustering of the resulting RNA- and ATAC-seq networks was performed based on the infomap (RNA-seq network 3-CePs and ATAC-seq network cisplatin) or walktrap (ATAC-seq network 3-CePs and RNA-seq cisplatin) algorithm, where a threshold of minimum of 15 nodes per cluster was applied (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B, C</xref>; <xref ref-type="bibr" rid="bib86">Rosvall et al., 2009</xref>). To select the threshold, we inspected different values from a minimum of 10 and chose such threshold empirically with the overall goal to maximize the number of detected modules with specific regulation patterns (also in horizontally integrated networks) without compromising the possibility to get efficient functional enrichments.</p><p>Subsequently, inter-omic integration by vCoCena was applied to construct the final network. In this case, the correlation between the mean GFC pattern of modules belonging to the two layers was calculated to identify clusters of genes with similar regulation, suitable for crosswise integration. The GFCs are obtained by calculating the mean expression of a gene over all conditions and then computing the fold change of the mean gene expression within each condition from the overall mean (<xref ref-type="bibr" rid="bib3">Aschenbrenner et al., 2021</xref>). Edges from the two separate networks were selected for contributing to the integrated one based on a minimum cross-layer correlation which could guarantee the maximum mixture between layers in identified module pairs (3-CePs: minimum correlation cutoff = 0.665, edges = 206200, and nodes = 3030; cisplatin: minimum correlation cutoff = 0.69, edges = 796517, and nodes = 3104). The new network was reclustered exploiting the walktrap (3-CePs) or infomap (cisplatin) algorithm, applying the same threshold of a minimum of 15 nodes per cluster, and mean GFCs were recalculated: the resulting integrated modules included nodes originally derived from the two separate layers in different ratios, as shown in the relative heatmap (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2E</xref>). Clustering algorithms were chosen empirically based on the evaluation of the resulting modules in terms of size, represented regulatory complexity/diversification as well as functional validity. GO-based GSEA was performed on detected modules of genes (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>) and the most significant terms (p&lt;0.05) were reported.</p></sec><sec id="s4-10"><title>Sensitivity signature construction and prediction pipeline</title><p>For the signature of sensitivity to <bold>M</bold> and cisplatin, relevant modules from the crosswise vCoCena integration were selected as follows (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>): for each module, in both cell lines separately, we calculated the difference between the GFC of the control and the <bold>M</bold> (or cisplatin) 6 hr treated groups (∆GFC [cell line]=GFC(<bold>M</bold>6h) − GFC [ctrl]). The early time point was selected to guide the signature construction since from upstream analyses it turned out to be the most informative of cell responses to 3-CePs. The threshold score was then calculated as the difference between the previously obtained ∆GFCs for the two cell lines (thr<sub>score</sub> = ∆GFC [BxPC-3] − ∆GFC [HCT-15]). Modules with thr<sub>score</sub> above q50, thus modules where the regulation was sufficiently different in the two cell lines after treatment with <bold>M</bold>, were selected (<bold>M</bold>: maroon, dark green, steelblue, indian red, light green, pink, sandy brown; cisplatin: orchid, maroon, dark orange, gold, indian red, light blue, and khaki). Genes from the identified modules were grouped together and further considered to drive the definition of our signature of interest.</p><p>Further on, DE analysis was performed between BxPC-3 and HCT-15 untreated control groups to identify baseline DE genes up- and down-regulated in the high-sensitive cell line (abs[log<sub>2</sub>FC]&gt;1 [<bold>M</bold>] or &gt;2.5 [cisplatin], padj &lt;0.01). In fact, given the much higher availability and clinical spendability of RNA-seq compared to ATAC-seq profiles, the signature was finally constructed only from basal transcriptomes. In particular, we further selected among the identified module genes only those that were also DE between the two untreated controls, ending up with a restricted group of genes showing compound- and cell line-specific regulation upon perturbation but, meanwhile, a significantly different basal expression in BxPC-3 cells. This perturbation-informed signature for <bold>M</bold> was composed of 307 genes upregulated (signature up) and 123 genes downregulated (signature down) in the high-sensitive BxPC-3 cells (listed in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). For cisplatin, the signature was composed by 107 genes upregulated (signature up) and 363 genes downregulated (signature down) in the high-sensitive Jurkat cells (<xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>).</p><p>To validate the predictive performance of the obtained signature, GSVA was performed both with up and down signatures on the basal RNA-seq profiles of cancer cell lines included in the HPA (human protein atlas) (<xref ref-type="bibr" rid="bib107">Uhlén et al., 2015</xref>). A sensitivity score was calculated for each cell line as the difference between the ESs of the up and the down signatures. The predicted rank was validated on selected cell lines (A-431, A549, HEK-293, NTERA-2, PC-3, and SH-SY5Y) as described in the next paragraph, and Pearson correlation between predicted sensitivity scores and viability decrease in cells treated with <bold>M</bold> 10 nM for 72 hr was calculated. Two control signatures of the same size were also tested: (1) a random genes signature (composed by random genes among those annotated in the RNA-seq profile of HPA cell lines) and (2) a control signature composed by the top up- and down- log<sub>2</sub>FC DE genes between the two cell lines (listed in <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). The cisplatin signature was also tested on HCA transcriptomes, subsetting for cancer cell lines whose IC<sub>50</sub> was available in the Genomics of Drug Sensitivity in Cancer database. Only cell lines with IC<sub>50</sub> no higher than the one of low-sensitive BxPC-3 cells (55 µM) were included in the correlation plot.</p><p>GSVA (v 1.38.2) was applied also on basal transcriptomes of samples from the Cancer Genome Atlas TCGA database, and their sensitivity score was calculated as previously indicated. The relative distribution of samples from different tumor types in terms of calculated sensitivity score was plotted together with the indicated median value for each group, to identify possibly more susceptible tumor types.</p><p>Finally, the signature-based prediction was used to train a LASSO-based classifier (<italic>cv.glmnet</italic> function in <italic>glmnet</italic> package v 4.1 to assess lambda penalty, predict function in stats package v 4.0.3 for actual prediction) (<xref ref-type="bibr" rid="bib29">Friedman et al., 2010</xref>). Briefly, TCGA samples were assigned to a continuous label based on the previously inferred sensitivity scores. We next trained the classifier with 80% of these profiles and tested it on the remaining 20%: Pearson correlation and RMSE were calculated to evaluate the predictive performance of the classifier. The classifier was also tested on separate tumor types to assess accuracy in predicting intra-tumor heterogeneity. To assess the biological robustness of our signature and of the obtained model, the classifier was trained and tested also using transcriptomes cleaned up from genes belonging to our signature.</p></sec><sec id="s4-11"><title>Validation of 3-CePs sensitivity prediction on cancer cell lines</title><p>The rank of sensitivity to <bold>M</bold> obtained from the newly constructed signature was validated on a subset of available cell lines included in the Human Cell Atlas. The selected cell lines spanned quite well between the max and min detected susceptibility scores. Here are the screened cell lines from the one predicted as most sensitive: PC-3, A549, A-431, SH-SY5Y, NTERA-2, and HEK-293. 5000 cells/well were seeded in 96-well microplates and after 24 hr treated with <bold>M</bold> 10 nM for 72 hr. Cell viability was assessed at the end of the treatment by MTT, following previously adopted protocols (<xref ref-type="bibr" rid="bib14">Carraro et al., 2019</xref>). Mean values of residual viability and SDs obtained from two independent experiments in duplicated microplates, each one containing three technical replicates, are reported in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. Pearson correlation between mean residual viability and predicted susceptibility score in considered cell lines was calculated and reported in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</p></sec><sec id="s4-12"><title>Statistics and reproducibility</title><p>Unpaired two-tailed Student’s <italic>t</italic>-test was performed to assess statistically significant differences (p&lt;0.05) in cell cycle and H2AX phosphorylation analyses between treated and control conditions (n=3). All correlation coefficients were calculated with a Pearson’s test. The adopted statistical tests, the considered significance levels, and the number of biological replicates are also reported in figure legends. Boxplots are in the style of Tukey, where the center of the box represents the median of values, hinges represent the 25th and 75th percentile, and the whiskers are extended not further than the 1.5×IQR (inter quartile range). The analysis was performed on R (v. 3.6.2 or 4.0.3): the specific packages used for the analysis, their version and relevant parameters used are explained in the Methods sections. All plots were generated with <italic>ggplot</italic> (v. 3.3.2) except for the heatmaps which were generated with the R package <italic>complexheatmap</italic> (v. 2.2.0). To ensure the reproducibility of the manuscript results, all the analyses were conducted within a containerized environment (Docker). RNA- and ATAC-seq analyses were performed with the docker image jsschrepping/r_docker:jss_R362 (<ext-link ext-link-type="uri" xlink:href="https://hub.docker.com/r/jsschrepping/r_docker">https://hub.docker.com/r/jsschrepping/r_docker</ext-link>). The rest of the analysis was conducted with the image lorenzobonaguro/cocena:v3 (<ext-link ext-link-type="uri" xlink:href="https://hub.docker.com/r/lorenzobonaguro/cocena">https://hub.docker.com/r/lorenzobonaguro/cocena</ext-link>) for compatibility with the CoCena pipeline.</p></sec><sec id="s4-13"><title>Data availability</title><p>All raw data included in this study are available at gene expression omnibus (GEO). For 3-CePs, raw RNA-seq data and count matrix are under the GEO accession number GSE179057. Raw ATAC-seq data and peak matrix are available under the accession number GSE179059. Both datasets are collected in a GEO SuperSeries (GSE179064). Cisplatin RNA-seq data and count matrix are available at the accession number GSE207611, the raw ATAC-seq data and peak matrix are available under the number GSE207607. Both are collected in a GEO SuperSeries (GSE207612).The cell line expression data employed in the prediction pipeline were downloaded from <ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/about/download">https://www.proteinatlas.org/about/download</ext-link>. The file RNA HPA cell line gene data contains transcript expression levels summarized per gene in 69 cell lines and is based on the Human Protein Atlas version 20.0 and Ensembl version 92.38.Similarly, the TCGA expression data from cancer cell samples (the Cancer Genome Atlas) were downloaded from the same web page of the Human Cell Atlas (Transcript expression levels summarized per gene in 7932 samples from 17 different cancer types). Data are based on The Human Protein Atlas version 20.0 and Ensembl version 92.38. Cisplatin IC<sub>50</sub>s in different cell lines can be accessed through the Genomics of Drug Sensitivity in Cancer database (<ext-link ext-link-type="uri" xlink:href="https://www.cancerrxgene.org/compound/Cisplatin/1005/overview/ic50">https://www.cancerrxgene.org/compound/Cisplatin/1005/overview/ic50</ext-link>) (<xref ref-type="bibr" rid="bib115">Yang et al., 2013</xref>). Codes to reproduce both pre-processing and downstream analyses reported in this manuscript are available at the public repository <ext-link ext-link-type="uri" xlink:href="https://github.com/ccarraro/3-CePs_prediction">https://github.com/ccarraro/3-CePs_prediction</ext-link>, (<xref ref-type="bibr" rid="bib16">Carraro, 2022</xref> copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:037a2595a4b7a7629f7cdfd1050fa01b706697a6;origin=https://github.com/ccarraro/3-CePs_prediction;visit=swh:1:snp:189c3b52405801f473950422162586e3c3dfb5c7;anchor=swh:1:rev:16c71c7857a4980f6ce2a054994d62b78a991e0d">swh:1:rev:16c71c7857a4980f6ce2a054994d62b78a991e0d</ext-link>). The hCoCena script is accessible at <ext-link ext-link-type="uri" xlink:href="https://github.com/MarieOestreich/hCoCena">https://github.com/MarieOestreich/hCoCena</ext-link> (<xref ref-type="bibr" rid="bib70">Oestreich, 2022</xref>, copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:d0edfa767ff398582a368310f289618ca9fae9af;origin=https://github.com/MarieOestreich/hCoCena;visit=swh:1:snp:7997f808e20bea2185c67b6b471662dd74a0feed;anchor=swh:1:rev:0ff2b77fa7371ce88801b5798dd3c87e0b03d2b1">swh:1:rev:0ff2b77fa7371ce88801b5798dd3c87e0b03d2b1</ext-link>) (vertical integration code available upon request). Supplementary Data are available as .xlsx or .pdf files.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Supervision, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Software, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Software, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Gene ontology (GO) enrichment results for differential expression (DE) genes sets reported in <xref ref-type="fig" rid="fig2">Figure 2C</xref> (BxPC-3 specific upregulated, HCT-15 specific upregulated, shared upregulated, BxPC-3 specific downregulated, HCT-15 specific downregulated, shared downregulated).</title></caption><media xlink:href="elife-78012-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Gene ontology (GO) enrichment results for genes belonging to the specified heatmap clusters reported in <xref ref-type="fig" rid="fig2">Figure 2D</xref> (BxPC-3 and HCT-15 cells DE genes after 6 hr of treatment) and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref> (BxPC-3 and HCT-15 cells differential expression DE genes after 12 hr of treatment).</title></caption><media xlink:href="elife-78012-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Gene ontology (GO) enrichment results for differentially accessible region (DAR)-associated genes belonging to the specified heatmap clusters reported in <xref ref-type="fig" rid="fig4">Figure 4C</xref> (BxPC-3 and HCT-15 cells DAR genes after 6 hr of treatment) and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref> (BxPC-3 and HCT-15 cells DAR-associated genes after 12 hr of treatment).</title></caption><media xlink:href="elife-78012-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Gene ontology (GO) enrichment results for detected vertical construction of co-expression network analysis (vCoCena) modules reported in <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</title></caption><media xlink:href="elife-78012-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Up and down sensitivity signature gene list for compound M.</title></caption><media xlink:href="elife-78012-supp5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Average viability decrease in cell lines treated with M 10 nM for 72 hr with associated SD.</title><p>For each cell line, predicted sensitivity scores based on our perturbation-informed signature (signature SS), a random one (random SS), a control one based on top up and down log<sub>2</sub>FC differential expression (DE) genes between BxPC-3 and HCT-15 (topFC SS) were also reported.</p></caption><media xlink:href="elife-78012-supp6-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Top up and down log<sub>2</sub>FC control sensitivity signature gene list used as control.</title></caption><media xlink:href="elife-78012-supp7-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Up and down sensitivity signature gene list for cisplatin.</title></caption><media xlink:href="elife-78012-supp8-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp9"><label>Supplementary file 9.</label><caption><title>Reported IC<sub>50</sub> for cell lines treated with cisplatin (Genomics of Drug Sensitivity in Cancer database).</title><p>For each cell line, predicted sensitivity scores based on our perturbation-informed signature are reported (signature SS).</p></caption><media xlink:href="elife-78012-supp9-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp10"><label>Supplementary file 10.</label><caption><title>Enrichment maps obtained for each group of genes depicted in the <xref ref-type="fig" rid="fig2">Figure 2C</xref> dotplot.</title></caption><media xlink:href="elife-78012-supp10-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-78012-transrepform1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All raw data included in this study are available at gene expression omnibus (GEO). For 3-CePs, raw RNA-seq data and count matrix are under the GEO accession number GSE179057. Raw ATAC-seq data and peak matrix are available under the accession number GSE179059. Both datasets are collected in a GEO SuperSeries (GSE179064). Cisplatin RNA-seq data and count matrix are available at the accession number GSE207611, the raw ATAC-seq data and peak matrix are available under the number GSE207607. Both are collected in a GEO SuperSeries (GSE207612). The cell line expression data employed in the prediction pipeline were downloaded from <ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/about/download">https://www.proteinatlas.org/about/download</ext-link>. The file RNA HPA cell line gene data contains transcript expression levels summarized per gene in 69 cell lines and is based on the Human Protein Atlas version 20.0 and Ensembl version 92.38. Similarly, the TCGA expression data from cancer cell samples (the Cancer Genome Atlas) were downloaded from the same web page of the Human Cell Atlas (Transcript expression levels summarized per gene in 7932 samples from 17 different cancer types). Data are based on The Human Protein Atlas version 20.0 and Ensembl version 92.38. Cisplatin IC<sub>50</sub>s in different cell lines can be accessed through the Genomics of Drug Sensitivity in Cancer database (<ext-link ext-link-type="uri" xlink:href="https://www.cancerrxgene.org/compound/Cisplatin/1005/overview/ic50">https://www.cancerrxgene.org/compound/Cisplatin/1005/overview/ic50</ext-link>) (Yang et al., 2013). Codes to reproduce both pre-processing and downstream analyses reported in this manuscript are available at the public repository <ext-link ext-link-type="uri" xlink:href="https://github.com/ccarraro/3-CePs_prediction">https://github.com/ccarraro/3-CePs_prediction</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:037a2595a4b7a7629f7cdfd1050fa01b706697a6;origin=https://github.com/ccarraro/3-CePs_prediction;visit=swh:1:snp:189c3b52405801f473950422162586e3c3dfb5c7;anchor=swh:1:rev:16c71c7857a4980f6ce2a054994d62b78a991e0d">swh:1:rev:16c71c7857a4980f6ce2a054994d62b78a991e0d</ext-link>). The hCoCena script is accessible at <ext-link ext-link-type="uri" xlink:href="https://github.com/MarieOestreich/hCoCena">https://github.com/MarieOestreich/hCoCena</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:d0edfa767ff398582a368310f289618ca9fae9af;origin=https://github.com/MarieOestreich/hCoCena;visit=swh:1:snp:7997f808e20bea2185c67b6b471662dd74a0feed;anchor=swh:1:rev:0ff2b77fa7371ce88801b5798dd3c87e0b03d2b1">swh:1:rev:0ff2b77fa7371ce88801b5798dd3c87e0b03d2b1</ext-link>) (vertical integration code available upon request). Supplementary Data are available as .xlsx or .pdf files.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>C</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Perturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE179064">GSE179064</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>C</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Perturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs (cisplatin validation dataset)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE207612">GSE207612</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>C</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Perturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs [RNA-seq]</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE179057">GSE179057</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset4"><person-group person-group-type="author"><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Perturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs [ATAC-seq]</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE179059">GSE179059</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset5"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>C</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Perturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs (cisplatin validation dataset) [ATAC-seq]</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE207611">GSE207611</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset6"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>C</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Perturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs (cisplatin validation dataset) [RNA-seq]</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE207607">GSE207607</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset7"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>C</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Perturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA742032">PRJNA742032</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>Funding HGF Helmholtz AI grant Pro-Gene-Gen (ZT-I-PF5-23) Marie Oestreich German Research Foundation (DFG) Excellence Strategy (EXC2151-390873048) German Research Foundation (DFG) - SCHU 950/8–1 German Research Foundation (DFG) - GRK 2168 German Research Foundation (DFG) - TP11 German Research Foundation (DFG) - SFB704 BMBF-funded excellence project Diet–Body–Brain (DietBB) EU project SYSCID under grant number 733100 Joachim L Schultze.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>AM</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Schug</surname><given-names>J</given-names></name><name><surname>Naji</surname><given-names>A</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Integration of ATAC-seq and RNA-seq identifies human alpha cell and beta cell signature genes</article-title><source>Molecular Metabolism</source><volume>5</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2016.01.002</pub-id><pub-id pub-id-type="pmid">26977395</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>G</given-names></name><name><surname>Rampášek</surname><given-names>L</given-names></name><name><surname>Safikhani</surname><given-names>Z</given-names></name><name><surname>Smirnov</surname><given-names>P</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Goldenberg</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Machine learning approaches to drug response prediction: challenges and recent progress</article-title><source>NPJ Precision Oncology</source><volume>4</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.1038/s41698-020-0122-1</pub-id><pub-id pub-id-type="pmid">32566759</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aschenbrenner</surname><given-names>AC</given-names></name><name><surname>Mouktaroudi</surname><given-names>M</given-names></name><name><surname>Krämer</surname><given-names>B</given-names></name><name><surname>Oestreich</surname><given-names>M</given-names></name><name><surname>Antonakos</surname><given-names>N</given-names></name><name><surname>Nuesch-Germano</surname><given-names>M</given-names></name><name><surname>Gkizeli</surname><given-names>K</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>Reusch</surname><given-names>N</given-names></name><name><surname>Baßler</surname><given-names>K</given-names></name><name><surname>Saridaki</surname><given-names>M</given-names></name><name><surname>Knoll</surname><given-names>R</given-names></name><name><surname>Pecht</surname><given-names>T</given-names></name><name><surname>Kapellos</surname><given-names>TS</given-names></name><name><surname>Doulou</surname><given-names>S</given-names></name><name><surname>Kröger</surname><given-names>C</given-names></name><name><surname>Herbert</surname><given-names>M</given-names></name><name><surname>Holsten</surname><given-names>L</given-names></name><name><surname>Horne</surname><given-names>A</given-names></name><name><surname>Gemünd</surname><given-names>ID</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients</article-title><source>Genome Medicine</source><volume>13</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-020-00823-5</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barretina</surname><given-names>J</given-names></name><name><surname>Caponigro</surname><given-names>G</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Venkatesan</surname><given-names>K</given-names></name><name><surname>Margolin</surname><given-names>AA</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>CJ</given-names></name><name><surname>Lehár</surname><given-names>J</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Sonkin</surname><given-names>D</given-names></name><name><surname>Reddy</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Murray</surname><given-names>L</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Monahan</surname><given-names>JE</given-names></name><name><surname>Morais</surname><given-names>P</given-names></name><name><surname>Meltzer</surname><given-names>J</given-names></name><name><surname>Korejwa</surname><given-names>A</given-names></name><name><surname>Jané-Valbuena</surname><given-names>J</given-names></name><name><surname>Mapa</surname><given-names>FA</given-names></name><name><surname>Thibault</surname><given-names>J</given-names></name><name><surname>Bric-Furlong</surname><given-names>E</given-names></name><name><surname>Raman</surname><given-names>P</given-names></name><name><surname>Shipway</surname><given-names>A</given-names></name><name><surname>Engels</surname><given-names>IH</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>GK</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Aspesi</surname><given-names>P</given-names><suffix>Jr</suffix></name><name><surname>de Silva</surname><given-names>M</given-names></name><name><surname>Jagtap</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>MD</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hatton</surname><given-names>C</given-names></name><name><surname>Palescandolo</surname><given-names>E</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Mahan</surname><given-names>S</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Onofrio</surname><given-names>RC</given-names></name><name><surname>Liefeld</surname><given-names>T</given-names></name><name><surname>MacConaill</surname><given-names>L</given-names></name><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Reich</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Myer</surname><given-names>VE</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Porter</surname><given-names>J</given-names></name><name><surname>Warmuth</surname><given-names>M</given-names></name><name><surname>Finan</surname><given-names>P</given-names></name><name><surname>Harris</surname><given-names>JL</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Morrissey</surname><given-names>MP</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title><source>Nature</source><volume>483</volume><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/nature11003</pub-id><pub-id pub-id-type="pmid">22460905</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Trimmomatic: a flexible trimmer for illumina sequence data</article-title><source>Bioinformatics</source><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brabletz</surname><given-names>T</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name><name><surname>Nieto</surname><given-names>MA</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>EMT in cancer</article-title><source>Nature Reviews. Cancer</source><volume>18</volume><fpage>128</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.118</pub-id><pub-id pub-id-type="pmid">29326430</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>AJ</given-names></name><name><surname>Putoczki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>JAK-STAT signalling pathway in cancer</article-title><source>Cancers</source><volume>12</volume><elocation-id>E1971</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12071971</pub-id><pub-id pub-id-type="pmid">32698360</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunen</surname><given-names>D</given-names></name><name><surname>Willems</surname><given-names>SM</given-names></name><name><surname>Kellner</surname><given-names>U</given-names></name><name><surname>Midgley</surname><given-names>R</given-names></name><name><surname>Simon</surname><given-names>I</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TGF-β: an emerging player in drug resistance</article-title><source>Cell Cycle</source><volume>12</volume><fpage>2960</fpage><lpage>2968</lpage><pub-id pub-id-type="doi">10.4161/cc.26034</pub-id><pub-id pub-id-type="pmid">23974105</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buenrostro</surname><given-names>JD</given-names></name><name><surname>Giresi</surname><given-names>PG</given-names></name><name><surname>Zaba</surname><given-names>LC</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Greenleaf</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position</article-title><source>Nature Methods</source><volume>10</volume><fpage>1213</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2688</pub-id><pub-id pub-id-type="pmid">24097267</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>K</given-names></name><name><surname>Mühl</surname><given-names>B</given-names></name><name><surname>Harasim</surname><given-names>T</given-names></name><name><surname>Rohrmoser</surname><given-names>M</given-names></name><name><surname>Malamoussi</surname><given-names>A</given-names></name><name><surname>Orban</surname><given-names>M</given-names></name><name><surname>Kellner</surname><given-names>M</given-names></name><name><surname>Gruber-Eber</surname><given-names>A</given-names></name><name><surname>Kremmer</surname><given-names>E</given-names></name><name><surname>Hölzel</surname><given-names>M</given-names></name><name><surname>Eick</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Chemotherapeutic drugs inhibit ribosome biogenesis at various levels</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>12416</fpage><lpage>12425</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.074211</pub-id><pub-id pub-id-type="pmid">20159984</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>EC</given-names></name><name><surname>Ray</surname><given-names>F</given-names></name><name><surname>Alvarez</surname><given-names>MJ</given-names></name><name><surname>Realubit</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Karan</surname><given-names>C</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name><name><surname>Sims</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PLATE-seq for genome-wide regulatory network analysis of high-throughput screens</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>105</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-00136-z</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantor</surname><given-names>SB</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>Kass</surname><given-names>EM</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Grossman</surname><given-names>S</given-names></name><name><surname>Wahrer</surname><given-names>DC</given-names></name><name><surname>Sgroi</surname><given-names>DC</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function</article-title><source>Cell</source><volume>105</volume><fpage>149</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(01)00304-x</pub-id><pub-id pub-id-type="pmid">11301010</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caridi</surname><given-names>CP</given-names></name><name><surname>Plessner</surname><given-names>M</given-names></name><name><surname>Grosse</surname><given-names>R</given-names></name><name><surname>Chiolo</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nuclear actin filaments in DNA repair dynamics</article-title><source>Nature Cell Biology</source><volume>21</volume><fpage>1068</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0379-1</pub-id><pub-id pub-id-type="pmid">31481797</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>C</given-names></name><name><surname>Francke</surname><given-names>A</given-names></name><name><surname>Sosic</surname><given-names>A</given-names></name><name><surname>Kohl</surname><given-names>F</given-names></name><name><surname>Helbing</surname><given-names>T</given-names></name><name><surname>De Franco</surname><given-names>M</given-names></name><name><surname>Fabris</surname><given-names>D</given-names></name><name><surname>Göttlich</surname><given-names>R</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Behind the mirror: chirality tunes the reactivity and cytotoxicity of chloropiperidines as potential anticancer agents</article-title><source>ACS Medicinal Chemistry Letters</source><volume>10</volume><fpage>552</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.8b00580</pub-id><pub-id pub-id-type="pmid">30996795</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>C</given-names></name><name><surname>Helbing</surname><given-names>T</given-names></name><name><surname>Francke</surname><given-names>A</given-names></name><name><surname>Zuravka</surname><given-names>I</given-names></name><name><surname>Sosic</surname><given-names>A</given-names></name><name><surname>De Franco</surname><given-names>M</given-names></name><name><surname>Gandin</surname><given-names>V</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name><name><surname>Göttlich</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Appended aromatic moieties in flexible bis-3-chloropiperidines confer tropism against pancreatic cancer cells</article-title><source>ChemMedChem</source><volume>16</volume><fpage>860</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1002/cmdc.202000814</pub-id><pub-id pub-id-type="pmid">33200541</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>3-ceps_prediction</data-title><version designator="swh:1:rev:16c71c7857a4980f6ce2a054994d62b78a991e0d">swh:1:rev:16c71c7857a4980f6ce2a054994d62b78a991e0d</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:037a2595a4b7a7629f7cdfd1050fa01b706697a6;origin=https://github.com/ccarraro/3-CePs_prediction;visit=swh:1:snp:189c3b52405801f473950422162586e3c3dfb5c7;anchor=swh:1:rev:16c71c7857a4980f6ce2a054994d62b78a991e0d">https://archive.softwareheritage.org/swh:1:dir:037a2595a4b7a7629f7cdfd1050fa01b706697a6;origin=https://github.com/ccarraro/3-CePs_prediction;visit=swh:1:snp:189c3b52405801f473950422162586e3c3dfb5c7;anchor=swh:1:rev:16c71c7857a4980f6ce2a054994d62b78a991e0d</ext-link></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting autophagy to overcome drug resistance: further developments</article-title><source>Journal of Hematology &amp; Oncology</source><volume>13</volume><elocation-id>159</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-020-01000-2</pub-id><pub-id pub-id-type="pmid">33239065</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charles Richard</surname><given-names>JL</given-names></name><name><surname>Shukla</surname><given-names>MS</given-names></name><name><surname>Menoni</surname><given-names>H</given-names></name><name><surname>Ouararhni</surname><given-names>K</given-names></name><name><surname>Lone</surname><given-names>IN</given-names></name><name><surname>Roulland</surname><given-names>Y</given-names></name><name><surname>Papin</surname><given-names>C</given-names></name><name><surname>Ben Simon</surname><given-names>E</given-names></name><name><surname>Kundu</surname><given-names>T</given-names></name><name><surname>Hamiche</surname><given-names>A</given-names></name><name><surname>Angelov</surname><given-names>D</given-names></name><name><surname>Dimitrov</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>FACT assists base excision repair by boosting the remodeling activity of RSC</article-title><source>PLOS Genetics</source><volume>12</volume><elocation-id>e1006221</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006221</pub-id><pub-id pub-id-type="pmid">27467129</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Ahmed</surname><given-names>F</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Dykxhoorn</surname><given-names>DM</given-names></name><name><surname>Weinstock</surname><given-names>DM</given-names></name><name><surname>Pfeifer</surname><given-names>GP</given-names></name><name><surname>Lieberman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A PP4-phosphatase complex dephosphorylates gamma-H2AX generated during DNA replication</article-title><source>Molecular Cell</source><volume>31</volume><fpage>33</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.05.016</pub-id><pub-id pub-id-type="pmid">18614045</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corsello</surname><given-names>SM</given-names></name><name><surname>Nagari</surname><given-names>RT</given-names></name><name><surname>Spangler</surname><given-names>RD</given-names></name><name><surname>Rossen</surname><given-names>J</given-names></name><name><surname>Kocak</surname><given-names>M</given-names></name><name><surname>Bryan</surname><given-names>JG</given-names></name><name><surname>Humeidi</surname><given-names>R</given-names></name><name><surname>Peck</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>AA</given-names></name><name><surname>Wang</surname><given-names>VM</given-names></name><name><surname>Bender</surname><given-names>SA</given-names></name><name><surname>Lemire</surname><given-names>E</given-names></name><name><surname>Narayan</surname><given-names>R</given-names></name><name><surname>Montgomery</surname><given-names>P</given-names></name><name><surname>Ben-David</surname><given-names>U</given-names></name><name><surname>Garvie</surname><given-names>CW</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Rees</surname><given-names>MG</given-names></name><name><surname>Lyons</surname><given-names>NJ</given-names></name><name><surname>McFarland</surname><given-names>JM</given-names></name><name><surname>Wong</surname><given-names>BT</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Dumont</surname><given-names>N</given-names></name><name><surname>O’Hearn</surname><given-names>PJ</given-names></name><name><surname>Stefan</surname><given-names>E</given-names></name><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Harrington</surname><given-names>CN</given-names></name><name><surname>Greulich</surname><given-names>H</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Bittker</surname><given-names>JA</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Mader</surname><given-names>CC</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling</article-title><source>Nature Cancer</source><volume>1</volume><fpage>235</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/s43018-019-0018-6</pub-id><pub-id pub-id-type="pmid">32613204</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dugger</surname><given-names>SA</given-names></name><name><surname>Platt</surname><given-names>A</given-names></name><name><surname>Goldstein</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Drug development in the era of precision medicine</article-title><source>Nature Reviews. Drug Discovery</source><volume>17</volume><fpage>183</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.226</pub-id><pub-id pub-id-type="pmid">29217837</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>R</given-names></name><name><surname>Mueller</surname><given-names>B</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name><name><surname>Schlieker</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The otubain YOD1 is a deubiquitinating enzyme that associates with p97 to facilitate protein dislocation from the ER</article-title><source>Molecular Cell</source><volume>36</volume><fpage>28</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2009.09.016</pub-id><pub-id pub-id-type="pmid">19818707</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eskelinen</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy</article-title><source>Molecular Aspects of Medicine</source><volume>27</volume><fpage>495</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2006.08.005</pub-id><pub-id pub-id-type="pmid">16973206</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faivre</surname><given-names>EJ</given-names></name><name><surname>McDaniel</surname><given-names>KF</given-names></name><name><surname>Albert</surname><given-names>DH</given-names></name><name><surname>Mantena</surname><given-names>SR</given-names></name><name><surname>Plotnik</surname><given-names>JP</given-names></name><name><surname>Wilcox</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bui</surname><given-names>MH</given-names></name><name><surname>Sheppard</surname><given-names>GS</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Sehgal</surname><given-names>V</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Uziel</surname><given-names>T</given-names></name><name><surname>Hessler</surname><given-names>P</given-names></name><name><surname>Lam</surname><given-names>LT</given-names></name><name><surname>Bellin</surname><given-names>RJ</given-names></name><name><surname>Mehta</surname><given-names>G</given-names></name><name><surname>Fidanze</surname><given-names>S</given-names></name><name><surname>Pratt</surname><given-names>JK</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Hasvold</surname><given-names>LA</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Panchal</surname><given-names>SC</given-names></name><name><surname>Nicolette</surname><given-names>JJ</given-names></name><name><surname>Fossey</surname><given-names>SL</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Longenecker</surname><given-names>K</given-names></name><name><surname>Bigelow</surname><given-names>L</given-names></name><name><surname>Torrent</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>SH</given-names></name><name><surname>Kati</surname><given-names>WM</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer</article-title><source>Nature</source><volume>578</volume><fpage>306</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1930-8</pub-id><pub-id pub-id-type="pmid">31969702</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferretti</surname><given-names>LP</given-names></name><name><surname>Himmels</surname><given-names>S-F</given-names></name><name><surname>Trenner</surname><given-names>A</given-names></name><name><surname>Walker</surname><given-names>C</given-names></name><name><surname>von Aesch</surname><given-names>C</given-names></name><name><surname>Eggenschwiler</surname><given-names>A</given-names></name><name><surname>Murina</surname><given-names>O</given-names></name><name><surname>Enchev</surname><given-names>RI</given-names></name><name><surname>Peter</surname><given-names>M</given-names></name><name><surname>Freire</surname><given-names>R</given-names></name><name><surname>Porro</surname><given-names>A</given-names></name><name><surname>Sartori</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cullin3-KLHL15 ubiquitin ligase mediates ctip protein turnover to fine-tune DNA-end resection</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>12628</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms12628</pub-id><pub-id pub-id-type="pmid">27561354</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortini</surname><given-names>P</given-names></name><name><surname>Pascucci</surname><given-names>B</given-names></name><name><surname>Parlanti</surname><given-names>E</given-names></name><name><surname>D’Errico</surname><given-names>M</given-names></name><name><surname>Simonelli</surname><given-names>V</given-names></name><name><surname>Dogliotti</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The base excision repair: mechanisms and its relevance for cancer susceptibility</article-title><source>Biochimie</source><volume>85</volume><fpage>1053</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2003.11.003</pub-id><pub-id pub-id-type="pmid">14726013</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fousteri</surname><given-names>M</given-names></name><name><surname>Mullenders</surname><given-names>LHF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects</article-title><source>Cell Research</source><volume>18</volume><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.6</pub-id><pub-id pub-id-type="pmid">18166977</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regularization paths for generalized linear models via coordinate descent</article-title><source>Journal of Statistical Software</source><volume>33</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.18637/jss.v033.i01</pub-id><pub-id pub-id-type="pmid">20808728</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Carbonero</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Cabeza-Morales</surname><given-names>M</given-names></name><name><surname>Martinez-Useros</surname><given-names>J</given-names></name><name><surname>Garcia-Foncillas</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>New hope for pancreatic ductal adenocarcinoma treatment targeting endoplasmic reticulum stress response: A systematic review</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>E2468</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19092468</pub-id><pub-id pub-id-type="pmid">30134550</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentleman</surname><given-names>RC</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name><name><surname>Bates</surname><given-names>DM</given-names></name><name><surname>Bolstad</surname><given-names>B</given-names></name><name><surname>Dettling</surname><given-names>M</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name><name><surname>Ellis</surname><given-names>B</given-names></name><name><surname>Gautier</surname><given-names>L</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Gentry</surname><given-names>J</given-names></name><name><surname>Hornik</surname><given-names>K</given-names></name><name><surname>Hothorn</surname><given-names>T</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Iacus</surname><given-names>S</given-names></name><name><surname>Irizarry</surname><given-names>R</given-names></name><name><surname>Leisch</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Maechler</surname><given-names>M</given-names></name><name><surname>Rossini</surname><given-names>AJ</given-names></name><name><surname>Sawitzki</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Smyth</surname><given-names>G</given-names></name><name><surname>Tierney</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>JYH</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Bioconductor: open software development for computational biology and bioinformatics</article-title><source>Genome Biology</source><volume>5</volume><elocation-id>R80</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2004-5-10-r80</pub-id><pub-id pub-id-type="pmid">15461798</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González-Quiroz</surname><given-names>M</given-names></name><name><surname>Blondel</surname><given-names>A</given-names></name><name><surname>Sagredo</surname><given-names>A</given-names></name><name><surname>Hetz</surname><given-names>C</given-names></name><name><surname>Chevet</surname><given-names>E</given-names></name><name><surname>Pedeux</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>When endoplasmic reticulum proteostasis meets the DNA damage response</article-title><source>Trends in Cell Biology</source><volume>30</volume><fpage>881</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2020.09.002</pub-id><pub-id pub-id-type="pmid">33036871</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granja</surname><given-names>JM</given-names></name><name><surname>Klemm</surname><given-names>S</given-names></name><name><surname>McGinnis</surname><given-names>LM</given-names></name><name><surname>Kathiria</surname><given-names>AS</given-names></name><name><surname>Mezger</surname><given-names>A</given-names></name><name><surname>Corces</surname><given-names>MR</given-names></name><name><surname>Parks</surname><given-names>B</given-names></name><name><surname>Gars</surname><given-names>E</given-names></name><name><surname>Liedtke</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>GXY</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Majeti</surname><given-names>R</given-names></name><name><surname>Greenleaf</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia</article-title><source>Nature Biotechnology</source><volume>37</volume><fpage>1458</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0332-7</pub-id><pub-id pub-id-type="pmid">31792411</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>SH</given-names></name><name><surname>Hur</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>YH</given-names></name><name><surname>Gildersleeve</surname><given-names>R</given-names></name><name><surname>Shan</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>CL</given-names></name><name><surname>Krokowski</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Hatzoglou</surname><given-names>M</given-names></name><name><surname>Kilberg</surname><given-names>MS</given-names></name><name><surname>Sartor</surname><given-names>MA</given-names></name><name><surname>Kaufman</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>481</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1038/ncb2738</pub-id><pub-id pub-id-type="pmid">23624402</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helbing</surname><given-names>T</given-names></name><name><surname>Carraro</surname><given-names>C</given-names></name><name><surname>Francke</surname><given-names>A</given-names></name><name><surname>Sosic</surname><given-names>A</given-names></name><name><surname>De Franco</surname><given-names>M</given-names></name><name><surname>Gandin</surname><given-names>V</given-names></name><name><surname>Göttlich</surname><given-names>R</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Aromatic linkers unleash the antiproliferative potential of 3-chloropiperidines against pancreatic cancer cells</article-title><source>ChemMedChem</source><volume>15</volume><fpage>2040</fpage><lpage>2051</lpage><pub-id pub-id-type="doi">10.1002/cmdc.202000457</pub-id><pub-id pub-id-type="pmid">32744774</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Höllbacher</surname><given-names>B</given-names></name><name><surname>Balázs</surname><given-names>K</given-names></name><name><surname>Heinig</surname><given-names>M</given-names></name><name><surname>Uhlenhaut</surname><given-names>NH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Seq-ing answers: current data integration approaches to uncover mechanisms of transcriptional regulation</article-title><source>Computational and Structural Biotechnology Journal</source><volume>18</volume><fpage>1330</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2020.05.018</pub-id><pub-id pub-id-type="pmid">32612756</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutt</surname><given-names>D</given-names></name><name><surname>Balch</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cell biology. The proteome in balance</article-title><source>Science</source><volume>329</volume><fpage>766</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1126/science.1194160</pub-id><pub-id pub-id-type="pmid">20705837</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaafar</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Dynan</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SFPQ•NONO and XLF function separately and together to promote DNA double-strand break repair via canonical nonhomologous end joining</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>1848</fpage><lpage>1859</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1209</pub-id><pub-id pub-id-type="pmid">27924002</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RD</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination</article-title><source>Nature</source><volume>401</volume><fpage>397</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1038/43932</pub-id><pub-id pub-id-type="pmid">10517641</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jozsef</surname><given-names>L</given-names></name><name><surname>Tashiro</surname><given-names>K</given-names></name><name><surname>Kuo</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>EJ</given-names></name><name><surname>Skoura</surname><given-names>A</given-names></name><name><surname>Albinsson</surname><given-names>S</given-names></name><name><surname>Rivera-Molina</surname><given-names>F</given-names></name><name><surname>Harrison</surname><given-names>KD</given-names></name><name><surname>Iwakiri</surname><given-names>Y</given-names></name><name><surname>Toomre</surname><given-names>D</given-names></name><name><surname>Sessa</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reticulon 4 is necessary for endoplasmic reticulum tubulation, STIM1-orai1 coupling, and store-operated calcium entry</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>9380</fpage><lpage>9395</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.548602</pub-id><pub-id pub-id-type="pmid">24558039</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagohara</surname><given-names>LT</given-names></name><name><surname>Zamuner</surname><given-names>F</given-names></name><name><surname>Davis-Marcisak</surname><given-names>EF</given-names></name><name><surname>Sharma</surname><given-names>G</given-names></name><name><surname>Considine</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name><name><surname>Yegnasubramanian</surname><given-names>S</given-names></name><name><surname>Gaykalova</surname><given-names>DA</given-names></name><name><surname>Fertig</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines</article-title><source>British Journal of Cancer</source><volume>123</volume><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-0851-5</pub-id><pub-id pub-id-type="pmid">32362655</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>WK</given-names></name><name><surname>Paules</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>DNA damage and cell cycle checkpoints</article-title><source>FASEB Journal</source><volume>10</volume><fpage>238</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1096/fasebj.10.2.8641557</pub-id><pub-id pub-id-type="pmid">8641557</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelland</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The resurgence of platinum-based cancer chemotherapy</article-title><source>Nature Reviews. Cancer</source><volume>7</volume><fpage>573</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1038/nrc2167</pub-id><pub-id pub-id-type="pmid">17625587</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koromina</surname><given-names>M</given-names></name><name><surname>Pandi</surname><given-names>MT</given-names></name><name><surname>Patrinos</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Rethinking drug repositioning and development with artificial intelligence, machine learning, and omics</article-title><source>OMICS : A Journal of Integrative Biology</source><volume>23</volume><fpage>539</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1089/omi.2019.0151</pub-id><pub-id pub-id-type="pmid">31651216</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunkel</surname><given-names>TA</given-names></name><name><surname>Erie</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>DNA mismatch repair</article-title><source>Annual Review of Biochemistry</source><volume>74</volume><fpage>681</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.74.082803.133243</pub-id><pub-id pub-id-type="pmid">15952900</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>ED</given-names></name><name><surname>Peck</surname><given-names>D</given-names></name><name><surname>Modell</surname><given-names>JW</given-names></name><name><surname>Blat</surname><given-names>IC</given-names></name><name><surname>Wrobel</surname><given-names>MJ</given-names></name><name><surname>Lerner</surname><given-names>J</given-names></name><name><surname>Brunet</surname><given-names>JP</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>KN</given-names></name><name><surname>Reich</surname><given-names>M</given-names></name><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Haggarty</surname><given-names>SJ</given-names></name><name><surname>Clemons</surname><given-names>PA</given-names></name><name><surname>Wei</surname><given-names>R</given-names></name><name><surname>Carr</surname><given-names>SA</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease</article-title><source>Science</source><volume>313</volume><fpage>1929</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.1126/science.1132939</pub-id><pub-id pub-id-type="pmid">17008526</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Pagès</surname><given-names>H</given-names></name><name><surname>Aboyoun</surname><given-names>P</given-names></name><name><surname>Carlson</surname><given-names>M</given-names></name><name><surname>Gentleman</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>MT</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Software for computing and annotating genomic ranges</article-title><source>PLOS Computational Biology</source><volume>9</volume><elocation-id>e1003118</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003118</pub-id><pub-id pub-id-type="pmid">23950696</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leek</surname><given-names>JT</given-names></name><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Parker</surname><given-names>HS</given-names></name><name><surname>Jaffe</surname><given-names>AE</given-names></name><name><surname>Storey</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The sva package for removing batch effects and other unwanted variation in high-throughput experiments</article-title><source>Bioinformatics</source><volume>28</volume><fpage>882</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts034</pub-id><pub-id pub-id-type="pmid">22257669</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Bolderson</surname><given-names>E</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Muniandy</surname><given-names>PA</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Richard</surname><given-names>DJ</given-names></name><name><surname>Seidman</surname><given-names>M</given-names></name><name><surname>Pandita</surname><given-names>TK</given-names></name><name><surname>Khanna</surname><given-names>KK</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009a</year><article-title>HSSB1 and hssb2 form similar multiprotein complexes that participate in DNA damage response</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>23525</fpage><lpage>23531</lpage><pub-id pub-id-type="doi">10.1074/jbc.C109.039586</pub-id><pub-id pub-id-type="pmid">19605351</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Handsaker</surname><given-names>B</given-names></name><name><surname>Wysoker</surname><given-names>A</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Homer</surname><given-names>N</given-names></name><name><surname>Marth</surname><given-names>G</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009b</year><article-title>The sequence alignment/map format and samtools</article-title><source>Bioinformatics (Oxford, England)</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JM</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>CRL ubiquitin ligases and DNA damage response</article-title><source>Frontiers in Oncology</source><volume>2</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2012.00029</pub-id><pub-id pub-id-type="pmid">22655267</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XX</given-names></name><name><surname>Zheng</surname><given-names>HT</given-names></name><name><surname>Peng</surname><given-names>JJ</given-names></name><name><surname>Huang</surname><given-names>LY</given-names></name><name><surname>Shi</surname><given-names>DB</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines</article-title><source>International Journal of Clinical and Experimental Pathology</source><volume>7</volume><fpage>2729</fpage><lpage>2736</lpage><pub-id pub-id-type="pmid">24966994</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L-Y</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X-S</given-names></name><name><surname>Yang</surname><given-names>J-M</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>DNA repair pathways in cancer therapy and resistance</article-title><source>Frontiers in Pharmacology</source><volume>11</volume><elocation-id>629266</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2020.629266</pub-id><pub-id pub-id-type="pmid">33628188</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Advances in bulk and single-cell multi-omics approaches for systems biology and precision medicine</article-title><source>Briefings in Bioinformatics</source><volume>22</volume><elocation-id>bbab024</elocation-id><pub-id pub-id-type="doi">10.1093/bib/bbab024</pub-id><pub-id pub-id-type="pmid">33778867</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Liang</surname><given-names>SH</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Glucose metabolism on tumor plasticity, diagnosis, and treatment</article-title><source>Frontiers in Oncology</source><volume>10</volume><elocation-id>317</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.00317</pub-id><pub-id pub-id-type="pmid">32211335</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>End resection: a key step in homologous recombination and DNA double-strand break repair</article-title><source>GENOME Instability &amp; Disease</source><volume>2</volume><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s42764-020-00028-5</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Huen</surname><given-names>MSY</given-names></name><name><surname>Feng</surname><given-names>XH</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>AUNIP/c1orf135 directs DNA double-strand breaks towards the homologous recombination repair pathway</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>985</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01151-w</pub-id><pub-id pub-id-type="pmid">29042561</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with deseq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Yue</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Nickoloff</surname><given-names>JA</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>BCCIP regulates homologous recombination by distinct domains and suppresses spontaneous DNA damage</article-title><source>Nucleic Acids Research</source><volume>35</volume><fpage>7160</fpage><lpage>7170</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm732</pub-id><pub-id pub-id-type="pmid">17947333</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>H</given-names></name><name><surname>Hanison</surname><given-names>J</given-names></name><name><surname>Nirmalan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Omics”-informed drug and biomarker discovery: opportunities</article-title><source>Challenges and Future Perspectives. Proteomes</source><volume>4</volume><elocation-id>e4030028</elocation-id><pub-id pub-id-type="doi">10.3390/proteomes4030028</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazin</surname><given-names>AV</given-names></name><name><surname>Mazina</surname><given-names>OM</given-names></name><name><surname>Bugreev</surname><given-names>DV</given-names></name><name><surname>Rossi</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Rad54, the motor of homologous recombination</article-title><source>DNA Repair</source><volume>9</volume><fpage>286</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2009.12.006</pub-id><pub-id pub-id-type="pmid">20089461</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>JM</given-names></name><name><surname>Paolella</surname><given-names>BR</given-names></name><name><surname>Warren</surname><given-names>A</given-names></name><name><surname>Geiger-Schuller</surname><given-names>K</given-names></name><name><surname>Shibue</surname><given-names>T</given-names></name><name><surname>Rothberg</surname><given-names>M</given-names></name><name><surname>Kuksenko</surname><given-names>O</given-names></name><name><surname>Colgan</surname><given-names>WN</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Chambers</surname><given-names>E</given-names></name><name><surname>Dionne</surname><given-names>D</given-names></name><name><surname>Bender</surname><given-names>S</given-names></name><name><surname>Wolpin</surname><given-names>BM</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Tirosh</surname><given-names>I</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Aguirre</surname><given-names>AJ</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4296</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17440-w</pub-id><pub-id pub-id-type="pmid">32855387</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McVey</surname><given-names>M</given-names></name><name><surname>Khodaverdian</surname><given-names>VY</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Cerqueira</surname><given-names>PG</given-names></name><name><surname>Heyer</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Eukaryotic DNA polymerases in homologous recombination</article-title><source>Annual Review of Genetics</source><volume>50</volume><fpage>393</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-120215-035243</pub-id><pub-id pub-id-type="pmid">27893960</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyn</surname><given-names>RE</given-names></name><name><surname>Murray</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Cell cycle effects of alkylating agents</article-title><source>Pharmacology &amp; Therapeutics</source><volume>24</volume><fpage>147</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/0163-7258(84)90032-9</pub-id><pub-id pub-id-type="pmid">6379683</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modesti</surname><given-names>M</given-names></name><name><surname>Budzowska</surname><given-names>M</given-names></name><name><surname>Baldeyron</surname><given-names>C</given-names></name><name><surname>Demmers</surname><given-names>JAA</given-names></name><name><surname>Ghirlando</surname><given-names>R</given-names></name><name><surname>Kanaar</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>RAD51AP1 is a structure-specific DNA binding protein that stimulates joint molecule formation during RAD51-mediated homologous recombination</article-title><source>Molecular Cell</source><volume>28</volume><fpage>468</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.08.025</pub-id><pub-id pub-id-type="pmid">17996710</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mun</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>G</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A guide for bioinformaticians: ’omics-based drug discovery for precision oncology</article-title><source>Drug Discovery Today</source><volume>5</volume><elocation-id>30335-4</elocation-id><pub-id pub-id-type="doi">10.1016/j.drudis.2020.08.004</pub-id><pub-id pub-id-type="pmid">32828947</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nijman</surname><given-names>SMB</given-names></name><name><surname>Huang</surname><given-names>TT</given-names></name><name><surname>Dirac</surname><given-names>AMG</given-names></name><name><surname>Brummelkamp</surname><given-names>TR</given-names></name><name><surname>Kerkhoven</surname><given-names>RM</given-names></name><name><surname>D’Andrea</surname><given-names>AD</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The deubiquitinating enzyme USP1 regulates the fanconi anemia pathway</article-title><source>Molecular Cell</source><volume>17</volume><fpage>331</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2005.01.008</pub-id><pub-id pub-id-type="pmid">15694335</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niraj</surname><given-names>J</given-names></name><name><surname>Färkkilä</surname><given-names>A</given-names></name><name><surname>D’Andrea</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The fanconi anemia pathway in cancer</article-title><source>Annual Review of Cancer Biology</source><volume>3</volume><fpage>457</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1146/annurev-cancerbio-030617-050422</pub-id><pub-id pub-id-type="pmid">30882047</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Oestreich</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>HCoCena</data-title><version designator="swh:1:rev:0ff2b77fa7371ce88801b5798dd3c87e0b03d2b1">swh:1:rev:0ff2b77fa7371ce88801b5798dd3c87e0b03d2b1</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:d0edfa767ff398582a368310f289618ca9fae9af;origin=https://github.com/MarieOestreich/hCoCena;visit=swh:1:snp:7997f808e20bea2185c67b6b471662dd74a0feed;anchor=swh:1:rev:0ff2b77fa7371ce88801b5798dd3c87e0b03d2b1">https://archive.softwareheritage.org/swh:1:dir:d0edfa767ff398582a368310f289618ca9fae9af;origin=https://github.com/MarieOestreich/hCoCena;visit=swh:1:snp:7997f808e20bea2185c67b6b471662dd74a0feed;anchor=swh:1:rev:0ff2b77fa7371ce88801b5798dd3c87e0b03d2b1</ext-link></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overmeer</surname><given-names>RM</given-names></name><name><surname>Gourdin</surname><given-names>AM</given-names></name><name><surname>Giglia-Mari</surname><given-names>A</given-names></name><name><surname>Kool</surname><given-names>H</given-names></name><name><surname>Houtsmuller</surname><given-names>AB</given-names></name><name><surname>Siegal</surname><given-names>G</given-names></name><name><surname>Fousteri</surname><given-names>MI</given-names></name><name><surname>Mullenders</surname><given-names>LHF</given-names></name><name><surname>Vermeulen</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Replication factor C recruits DNA polymerase delta to sites of nucleotide excision repair but is not required for PCNA recruitment</article-title><source>Molecular and Cellular Biology</source><volume>30</volume><fpage>4828</fpage><lpage>4839</lpage><pub-id pub-id-type="doi">10.1128/MCB.00285-10</pub-id><pub-id pub-id-type="pmid">20713449</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paananen</surname><given-names>J</given-names></name><name><surname>Fortino</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An omics perspective on drug target discovery platforms</article-title><source>Briefings in Bioinformatics</source><volume>21</volume><fpage>1937</fpage><lpage>1953</lpage><pub-id pub-id-type="doi">10.1093/bib/bbz122</pub-id><pub-id pub-id-type="pmid">31774113</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>JL</given-names></name><name><surname>Tait</surname><given-names>PS</given-names></name><name><surname>Finch</surname><given-names>D</given-names></name><name><surname>Dianova</surname><given-names>II</given-names></name><name><surname>Edelmann</surname><given-names>MJ</given-names></name><name><surname>Khoronenkova</surname><given-names>SV</given-names></name><name><surname>Kessler</surname><given-names>BM</given-names></name><name><surname>Sharma</surname><given-names>RA</given-names></name><name><surname>McKenna</surname><given-names>WG</given-names></name><name><surname>Dianov</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ubiquitin ligase ARF-BP1/mule modulates base excision repair</article-title><source>The EMBO Journal</source><volume>28</volume><fpage>3207</fpage><lpage>3215</lpage><pub-id pub-id-type="doi">10.1038/emboj.2009.243</pub-id><pub-id pub-id-type="pmid">19713937</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascucci</surname><given-names>B</given-names></name><name><surname>Fragale</surname><given-names>A</given-names></name><name><surname>Marabitti</surname><given-names>V</given-names></name><name><surname>Leuzzi</surname><given-names>G</given-names></name><name><surname>Calcagnile</surname><given-names>AS</given-names></name><name><surname>Parlanti</surname><given-names>E</given-names></name><name><surname>Franchitto</surname><given-names>A</given-names></name><name><surname>Dogliotti</surname><given-names>E</given-names></name><name><surname>D’Errico</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CSA and CSB play a role in the response to DNA breaks</article-title><source>Oncotarget</source><volume>9</volume><fpage>11581</fpage><lpage>11591</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.24342</pub-id><pub-id pub-id-type="pmid">29545921</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennisi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Upstart DNA sequencers could be a “game changer.”</article-title><source>Science</source><volume>376</volume><fpage>1257</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.1126/science.add4867</pub-id><pub-id pub-id-type="pmid">35709273</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><name><surname>Zorin</surname><given-names>A</given-names></name><name><surname>Dass</surname><given-names>G</given-names></name><name><surname>Vu</surname><given-names>MT</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Glont</surname><given-names>M</given-names></name><name><surname>Vizcaíno</surname><given-names>JA</given-names></name><name><surname>Jarnuczak</surname><given-names>AF</given-names></name><name><surname>Petryszak</surname><given-names>R</given-names></name><name><surname>Ping</surname><given-names>P</given-names></name><name><surname>Hermjakob</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Quantifying the impact of public omics data</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>3512</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-11461-w</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piwko</surname><given-names>W</given-names></name><name><surname>Mlejnkova</surname><given-names>LJ</given-names></name><name><surname>Mutreja</surname><given-names>K</given-names></name><name><surname>Ranjha</surname><given-names>L</given-names></name><name><surname>Stafa</surname><given-names>D</given-names></name><name><surname>Smirnov</surname><given-names>A</given-names></name><name><surname>Brodersen</surname><given-names>MM</given-names></name><name><surname>Zellweger</surname><given-names>R</given-names></name><name><surname>Sturzenegger</surname><given-names>A</given-names></name><name><surname>Janscak</surname><given-names>P</given-names></name><name><surname>Lopes</surname><given-names>M</given-names></name><name><surname>Peter</surname><given-names>M</given-names></name><name><surname>Cejka</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The MMS22L-TONSL heterodimer directly promotes RAD51-dependent recombination upon replication stress</article-title><source>The EMBO Journal</source><volume>35</volume><fpage>2584</fpage><lpage>2601</lpage><pub-id pub-id-type="doi">10.15252/embj.201593132</pub-id><pub-id pub-id-type="pmid">27797818</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poletto</surname><given-names>M</given-names></name><name><surname>Lirussi</surname><given-names>L</given-names></name><name><surname>Wilson</surname><given-names>DM</given-names></name><name><surname>Tell</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nucleophosmin modulates stability, activity, and nucleolar accumulation of base excision repair proteins</article-title><source>Molecular Biology of the Cell</source><volume>25</volume><fpage>1641</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1091/mbc.E13-12-0717</pub-id><pub-id pub-id-type="pmid">24648491</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>SL</given-names></name><name><surname>Hansen</surname><given-names>RK</given-names></name><name><surname>Wagner</surname><given-names>SA</given-names></name><name><surname>van Cuijk</surname><given-names>L</given-names></name><name><surname>van Belle</surname><given-names>GJ</given-names></name><name><surname>Streicher</surname><given-names>W</given-names></name><name><surname>Wikström</surname><given-names>M</given-names></name><name><surname>Choudhary</surname><given-names>C</given-names></name><name><surname>Houtsmuller</surname><given-names>AB</given-names></name><name><surname>Marteijn</surname><given-names>JA</given-names></name><name><surname>Bekker-Jensen</surname><given-names>S</given-names></name><name><surname>Mailand</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RNF111/arkadia is a SUMO-targeted ubiquitin ligase that facilitates the DNA damage response</article-title><source>The Journal of Cell Biology</source><volume>201</volume><fpage>797</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1083/jcb.201212075</pub-id><pub-id pub-id-type="pmid">23751493</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>R</given-names></name><name><surname>Dianov</surname><given-names>GL</given-names></name><name><surname>Bohr</surname><given-names>VA</given-names></name><name><surname>Wilson</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>FEN1 stimulation of DNA polymerase beta mediates an excision step in mammalian long patch base excision repair</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>4460</fpage><lpage>4466</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.6.4460</pub-id><pub-id pub-id-type="pmid">10660619</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajendra</surname><given-names>E</given-names></name><name><surname>Garaycoechea</surname><given-names>JI</given-names></name><name><surname>Patel</surname><given-names>KJ</given-names></name><name><surname>Passmore</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Abundance of the fanconi anaemia core complex is regulated by the ruvbl1 and ruvbl2 AAA+ atpases</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>13736</fpage><lpage>13748</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1230</pub-id><pub-id pub-id-type="pmid">25428364</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramírez</surname><given-names>F</given-names></name><name><surname>Dündar</surname><given-names>F</given-names></name><name><surname>Diehl</surname><given-names>S</given-names></name><name><surname>Grüning</surname><given-names>BA</given-names></name><name><surname>Manke</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>DeepTools: a flexible platform for exploring deep-sequencing data</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>W187</fpage><lpage>W191</lpage><pub-id pub-id-type="doi">10.1093/nar/gku365</pub-id><pub-id pub-id-type="pmid">24799436</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Sharp</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2007">2007</year><chapter-title>Heat‐shock protein regulation of protein folding, protein degradation, protein function, and apoptosis</chapter-title><person-group person-group-type="editor"><name><surname>Lajtha</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>PH</given-names></name></person-group><source>Handbook of Neurochemistry and Molecular Neurobiology</source><publisher-name>Springer</publisher-name><fpage>89</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1007/978-0-387-30383-3_6</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rendeiro</surname><given-names>AF</given-names></name><name><surname>Krausgruber</surname><given-names>T</given-names></name><name><surname>Fortelny</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Penz</surname><given-names>T</given-names></name><name><surname>Farlik</surname><given-names>M</given-names></name><name><surname>Schuster</surname><given-names>LC</given-names></name><name><surname>Nemc</surname><given-names>A</given-names></name><name><surname>Tasnády</surname><given-names>S</given-names></name><name><surname>Réti</surname><given-names>M</given-names></name><name><surname>Mátrai</surname><given-names>Z</given-names></name><name><surname>Alpár</surname><given-names>D</given-names></name><name><surname>Bödör</surname><given-names>C</given-names></name><name><surname>Schmidl</surname><given-names>C</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>577</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-14081-6</pub-id><pub-id pub-id-type="pmid">31996669</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>F</given-names></name><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Shah</surname><given-names>D</given-names></name><name><surname>Kallen</surname><given-names>CB</given-names></name><name><surname>Rosas</surname><given-names>I</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Schriner</surname><given-names>D</given-names></name><name><surname>Barta</surname><given-names>J</given-names></name><name><surname>Shaghaghi</surname><given-names>H</given-names></name><name><surname>Hoek</surname><given-names>JB</given-names></name><name><surname>Mesaros</surname><given-names>C</given-names></name><name><surname>Choi</surname><given-names>AM</given-names></name><name><surname>Snyder</surname><given-names>NW</given-names></name><name><surname>Summer</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lipid synthesis is required to resolve endoplasmic reticulum stress and limit fibrotic responses in the lung</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>59</volume><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2017-0340OC</pub-id><pub-id pub-id-type="pmid">29465261</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosvall</surname><given-names>M</given-names></name><name><surname>Axelsson</surname><given-names>D</given-names></name><name><surname>Bergstrom</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The map equation</article-title><source>The European Physical Journal Special Topics</source><volume>178</volume><fpage>13</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1140/epjst/e2010-01179-1</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>MS</given-names></name><name><surname>Hanawalt</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>TFIIH-mediated nucleotide excision repair and initiation of mrna transcription in an optimized cell-free DNA repair and RNA transcription assay</article-title><source>Nucleic Acids Research</source><volume>24</volume><fpage>3576</fpage><lpage>3582</lpage><pub-id pub-id-type="doi">10.1093/nar/24.18.3576</pub-id><pub-id pub-id-type="pmid">8836185</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidl</surname><given-names>C</given-names></name><name><surname>Vladimer</surname><given-names>GI</given-names></name><name><surname>Rendeiro</surname><given-names>AF</given-names></name><name><surname>Schnabl</surname><given-names>S</given-names></name><name><surname>Krausgruber</surname><given-names>T</given-names></name><name><surname>Taubert</surname><given-names>C</given-names></name><name><surname>Krall</surname><given-names>N</given-names></name><name><surname>Pemovska</surname><given-names>T</given-names></name><name><surname>Araghi</surname><given-names>M</given-names></name><name><surname>Snijder</surname><given-names>B</given-names></name><name><surname>Hubmann</surname><given-names>R</given-names></name><name><surname>Ringler</surname><given-names>A</given-names></name><name><surname>Runggatscher</surname><given-names>K</given-names></name><name><surname>Demirtas</surname><given-names>D</given-names></name><name><surname>de la Fuente</surname><given-names>OL</given-names></name><name><surname>Hilgarth</surname><given-names>M</given-names></name><name><surname>Skrabs</surname><given-names>C</given-names></name><name><surname>Porpaczy</surname><given-names>E</given-names></name><name><surname>Gruber</surname><given-names>M</given-names></name><name><surname>Hoermann</surname><given-names>G</given-names></name><name><surname>Kubicek</surname><given-names>S</given-names></name><name><surname>Staber</surname><given-names>PB</given-names></name><name><surname>Shehata</surname><given-names>M</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name><name><surname>Jäger</surname><given-names>U</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL</article-title><source>Nature Chemical Biology</source><volume>15</volume><fpage>232</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0205-2</pub-id><pub-id pub-id-type="pmid">30692684</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schröder</surname><given-names>HC</given-names></name><name><surname>Batel</surname><given-names>R</given-names></name><name><surname>Schwertner</surname><given-names>H</given-names></name><name><surname>Boreiko</surname><given-names>O</given-names></name><name><surname>Müller</surname><given-names>WEG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Fast micromethod DNA single-strand-break assay</article-title><source>Methods in Molecular Biology</source><volume>314</volume><fpage>287</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1385/1-59259-973-7:287</pub-id><pub-id pub-id-type="pmid">16673889</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulze</surname><given-names>A</given-names></name><name><surname>Standera</surname><given-names>S</given-names></name><name><surname>Buerger</surname><given-names>E</given-names></name><name><surname>Kikkert</surname><given-names>M</given-names></name><name><surname>van Voorden</surname><given-names>S</given-names></name><name><surname>Wiertz</surname><given-names>E</given-names></name><name><surname>Koning</surname><given-names>F</given-names></name><name><surname>Kloetzel</surname><given-names>P-M</given-names></name><name><surname>Seeger</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The ubiquitin-domain protein HERP forms a complex with components of the endoplasmic reticulum associated degradation pathway</article-title><source>Journal of Molecular Biology</source><volume>354</volume><fpage>1021</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2005.10.020</pub-id><pub-id pub-id-type="pmid">16289116</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>DC</given-names></name><name><surname>Rhee</surname><given-names>DY</given-names></name><name><surname>Duda</surname><given-names>DM</given-names></name><name><surname>Kelsall</surname><given-names>IR</given-names></name><name><surname>Olszewski</surname><given-names>JL</given-names></name><name><surname>Paulo</surname><given-names>JA</given-names></name><name><surname>de Jong</surname><given-names>A</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name><name><surname>Alpi</surname><given-names>AF</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Schulman</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Two distinct types of E3 ligases work in unison to regulate substrate ubiquitylation</article-title><source>Cell</source><volume>166</volume><fpage>1198</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.07.027</pub-id><pub-id pub-id-type="pmid">27565346</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaheen</surname><given-names>S</given-names></name><name><surname>Fawaz</surname><given-names>F</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Büsselberg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Differential expression and pathway analysis in drug-resistant triple-negative breast cancer cell lines using rnaseq analysis</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>E1810</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19061810</pub-id><pub-id pub-id-type="pmid">29921827</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>K</given-names></name><name><surname>Almasan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Histone H2AX phosphorylation: a marker for DNA damage</article-title><source>Methods in Molecular Biology</source><volume>920</volume><fpage>613</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-998-3_40</pub-id><pub-id pub-id-type="pmid">22941631</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shenton</surname><given-names>D</given-names></name><name><surname>Smirnova</surname><given-names>JB</given-names></name><name><surname>Selley</surname><given-names>JN</given-names></name><name><surname>Carroll</surname><given-names>K</given-names></name><name><surname>Hubbard</surname><given-names>SJ</given-names></name><name><surname>Pavitt</surname><given-names>GD</given-names></name><name><surname>Ashe</surname><given-names>MP</given-names></name><name><surname>Grant</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Global translational responses to oxidative stress impact upon multiple levels of protein synthesis</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>29011</fpage><lpage>29021</lpage><pub-id pub-id-type="doi">10.1074/jbc.M601545200</pub-id><pub-id pub-id-type="pmid">16849329</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smirnova</surname><given-names>E</given-names></name><name><surname>Toueille</surname><given-names>M</given-names></name><name><surname>Markkanen</surname><given-names>E</given-names></name><name><surname>Hübscher</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The human checkpoint sensor and alternative DNA clamp rad9-rad1-hus1 modulates the activity of DNA ligase I, a component of the long-patch base excision repair machinery</article-title><source>The Biochemical Journal</source><volume>389</volume><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1042/BJ20050211</pub-id><pub-id pub-id-type="pmid">15871698</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sosic</surname><given-names>A</given-names></name><name><surname>Zuravka</surname><given-names>I</given-names></name><name><surname>Schmitt</surname><given-names>NK</given-names></name><name><surname>Miola</surname><given-names>A</given-names></name><name><surname>Göttlich</surname><given-names>R</given-names></name><name><surname>Fabris</surname><given-names>D</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Direct and topoisomerase II mediated DNA damage by bis-3-chloropiperidines: the importance of being an earnest G</article-title><source>ChemMedChem</source><volume>12</volume><fpage>1471</fpage><lpage>1479</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201700368</pub-id><pub-id pub-id-type="pmid">28724198</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivatsan</surname><given-names>SR</given-names></name><name><surname>McFaline-Figueroa</surname><given-names>JL</given-names></name><name><surname>Ramani</surname><given-names>V</given-names></name><name><surname>Saunders</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Packer</surname><given-names>J</given-names></name><name><surname>Pliner</surname><given-names>HA</given-names></name><name><surname>Jackson</surname><given-names>DL</given-names></name><name><surname>Daza</surname><given-names>RM</given-names></name><name><surname>Christiansen</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Steemers</surname><given-names>F</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Massively multiplex chemical transcriptomics at single-cell resolution</article-title><source>Science</source><volume>367</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1126/science.aax6234</pub-id><pub-id pub-id-type="pmid">31806696</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Narayan</surname><given-names>R</given-names></name><name><surname>Corsello</surname><given-names>SM</given-names></name><name><surname>Peck</surname><given-names>DD</given-names></name><name><surname>Natoli</surname><given-names>TE</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Gould</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>JF</given-names></name><name><surname>Tubelli</surname><given-names>AA</given-names></name><name><surname>Asiedu</surname><given-names>JK</given-names></name><name><surname>Lahr</surname><given-names>DL</given-names></name><name><surname>Hirschman</surname><given-names>JE</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Donahue</surname><given-names>M</given-names></name><name><surname>Julian</surname><given-names>B</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Wadden</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>IC</given-names></name><name><surname>Lam</surname><given-names>D</given-names></name><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Toder</surname><given-names>C</given-names></name><name><surname>Bagul</surname><given-names>M</given-names></name><name><surname>Orzechowski</surname><given-names>M</given-names></name><name><surname>Enache</surname><given-names>OM</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Johnson</surname><given-names>SA</given-names></name><name><surname>Lyons</surname><given-names>NJ</given-names></name><name><surname>Berger</surname><given-names>AH</given-names></name><name><surname>Shamji</surname><given-names>AF</given-names></name><name><surname>Brooks</surname><given-names>AN</given-names></name><name><surname>Vrcic</surname><given-names>A</given-names></name><name><surname>Flynn</surname><given-names>C</given-names></name><name><surname>Rosains</surname><given-names>J</given-names></name><name><surname>Takeda</surname><given-names>DY</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Davison</surname><given-names>D</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Hogstrom</surname><given-names>L</given-names></name><name><surname>Greenside</surname><given-names>P</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name><name><surname>Clemons</surname><given-names>PA</given-names></name><name><surname>Silver</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>W-N</given-names></name><name><surname>Read-Button</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Haggarty</surname><given-names>SJ</given-names></name><name><surname>Ronco</surname><given-names>LV</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Bittker</surname><given-names>JA</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Wong</surname><given-names>B</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</article-title><source>Cell</source><volume>171</volume><fpage>1437</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.049</pub-id><pub-id pub-id-type="pmid">29195078</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Onodera</surname><given-names>K</given-names></name><name><surname>Matsui</surname><given-names>K</given-names></name><name><surname>Seki</surname><given-names>M</given-names></name><name><surname>Esumi</surname><given-names>H</given-names></name><name><surname>Soga</surname><given-names>T</given-names></name><name><surname>Sugano</surname><given-names>S</given-names></name><name><surname>Kohno</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Tsuchihara</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Characterization of cancer omics and drug perturbations in panels of lung cancer cells</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>19529</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-55692-9</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadros</surname><given-names>S</given-names></name><name><surname>Shukla</surname><given-names>SK</given-names></name><name><surname>King</surname><given-names>RJ</given-names></name><name><surname>Gunda</surname><given-names>V</given-names></name><name><surname>Vernucci</surname><given-names>E</given-names></name><name><surname>Abrego</surname><given-names>J</given-names></name><name><surname>Chaika</surname><given-names>NV</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Lazenby</surname><given-names>AJ</given-names></name><name><surname>Berim</surname><given-names>L</given-names></name><name><surname>Grem</surname><given-names>J</given-names></name><name><surname>Sasson</surname><given-names>AR</given-names></name><name><surname>Singh</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>de novo</italic> lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer</article-title><source>Cancer Research</source><volume>77</volume><fpage>5503</fpage><lpage>5517</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-3062</pub-id><pub-id pub-id-type="pmid">28811332</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tafazzoli-Shadpour</surname><given-names>M</given-names></name><name><surname>Mohammadi</surname><given-names>E</given-names></name><name><surname>Torkashvand</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanics of actin filaments in cancer onset and progress</article-title><source>International Review of Cell and Molecular Biology</source><volume>355</volume><fpage>205</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/bs.ircmb.2020.05.002</pub-id><pub-id pub-id-type="pmid">32859371</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tellier</surname><given-names>M</given-names></name><name><surname>Chalmers</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The roles of the human SETMAR (metnase) protein in illegitimate DNA recombination and non-homologous end joining repair</article-title><source>DNA Repair</source><volume>80</volume><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2019.06.006</pub-id><pub-id pub-id-type="pmid">31238295</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsimberidou</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Targeted therapy in cancer</article-title><source>Cancer Chemotherapy and Pharmacology</source><volume>76</volume><fpage>1113</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1007/s00280-015-2861-1</pub-id><pub-id pub-id-type="pmid">26391154</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>LC</given-names></name><name><surname>Melendy</surname><given-names>T</given-names></name><name><surname>Beerman</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>DNA damage responses triggered by a highly cytotoxic monofunctional DNA alkylator, hedamycin, a pluramycin antitumor antibiotic</article-title><source>Molecular Cancer Therapeutics</source><volume>3</volume><fpage>577</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">15141015</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tung</surname><given-names>KL</given-names></name><name><surname>Chen</surname><given-names>KY</given-names></name><name><surname>Negrete</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Safi</surname><given-names>A</given-names></name><name><surname>Aljamal</surname><given-names>AA</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Crawford</surname><given-names>GE</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Hsu</surname><given-names>DS</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistance</article-title><source>Genes &amp; Diseases</source><volume>8</volume><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.gendis.2019.10.012</pub-id><pub-id pub-id-type="pmid">33997167</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlén</surname><given-names>M</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Hallström</surname><given-names>BM</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>Mardinoglu</surname><given-names>A</given-names></name><name><surname>Sivertsson</surname><given-names>Å</given-names></name><name><surname>Kampf</surname><given-names>C</given-names></name><name><surname>Sjöstedt</surname><given-names>E</given-names></name><name><surname>Asplund</surname><given-names>A</given-names></name><name><surname>Olsson</surname><given-names>I</given-names></name><name><surname>Edlund</surname><given-names>K</given-names></name><name><surname>Lundberg</surname><given-names>E</given-names></name><name><surname>Navani</surname><given-names>S</given-names></name><name><surname>Szigyarto</surname><given-names>CAK</given-names></name><name><surname>Odeberg</surname><given-names>J</given-names></name><name><surname>Djureinovic</surname><given-names>D</given-names></name><name><surname>Takanen</surname><given-names>JO</given-names></name><name><surname>Hober</surname><given-names>S</given-names></name><name><surname>Alm</surname><given-names>T</given-names></name><name><surname>Edqvist</surname><given-names>PH</given-names></name><name><surname>Berling</surname><given-names>H</given-names></name><name><surname>Tegel</surname><given-names>H</given-names></name><name><surname>Mulder</surname><given-names>J</given-names></name><name><surname>Rockberg</surname><given-names>J</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Schwenk</surname><given-names>JM</given-names></name><name><surname>Hamsten</surname><given-names>M</given-names></name><name><surname>von Feilitzen</surname><given-names>K</given-names></name><name><surname>Forsberg</surname><given-names>M</given-names></name><name><surname>Persson</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>F</given-names></name><name><surname>Zwahlen</surname><given-names>M</given-names></name><name><surname>von Heijne</surname><given-names>G</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><name><surname>Pontén</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tissue-based map of the human proteome</article-title><source>Science</source><volume>347</volume><elocation-id>1260419</elocation-id><pub-id pub-id-type="doi">10.1126/science.1260419</pub-id><pub-id pub-id-type="pmid">25613900</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Sjöstedt</surname><given-names>E</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Bidkhori</surname><given-names>G</given-names></name><name><surname>Benfeitas</surname><given-names>R</given-names></name><name><surname>Arif</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Edfors</surname><given-names>F</given-names></name><name><surname>Sanli</surname><given-names>K</given-names></name><name><surname>Feilitzen</surname><given-names>K</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>Lundberg</surname><given-names>E</given-names></name><name><surname>Hober</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Mattsson</surname><given-names>J</given-names></name><name><surname>Schwenk</surname><given-names>JM</given-names></name><name><surname>Brunnström</surname><given-names>H</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Ponten</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A pathology atlas of the human cancer transcriptome</article-title><source>Science</source><volume>357</volume><elocation-id>eaan2507</elocation-id><pub-id pub-id-type="doi">10.1126/science.aan2507</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urra</surname><given-names>H</given-names></name><name><surname>Dufey</surname><given-names>E</given-names></name><name><surname>Lisbona</surname><given-names>F</given-names></name><name><surname>Rojas-Rivera</surname><given-names>D</given-names></name><name><surname>Hetz</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>When ER stress reaches a dead end</article-title><source>Biochimica et Biophysica Acta</source><volume>1833</volume><fpage>3507</fpage><lpage>3517</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2013.07.024</pub-id><pub-id pub-id-type="pmid">23988738</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasan</surname><given-names>N</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A view on drug resistance in cancer</article-title><source>Nature</source><volume>575</volume><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1730-1</pub-id><pub-id pub-id-type="pmid">31723286</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnat-Herresthal</surname><given-names>S</given-names></name><name><surname>Schultze</surname><given-names>H</given-names></name><name><surname>Shastry</surname><given-names>KL</given-names></name><name><surname>Manamohan</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>V</given-names></name><name><surname>Sarveswara</surname><given-names>R</given-names></name><name><surname>Händler</surname><given-names>K</given-names></name><name><surname>Pickkers</surname><given-names>P</given-names></name><name><surname>Aziz</surname><given-names>NA</given-names></name><name><surname>Ktena</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>F</given-names></name><name><surname>Bitzer</surname><given-names>M</given-names></name><name><surname>Ossowski</surname><given-names>S</given-names></name><name><surname>Casadei</surname><given-names>N</given-names></name><name><surname>Herr</surname><given-names>C</given-names></name><name><surname>Petersheim</surname><given-names>D</given-names></name><name><surname>Behrends</surname><given-names>U</given-names></name><name><surname>Kern</surname><given-names>F</given-names></name><name><surname>Fehlmann</surname><given-names>T</given-names></name><name><surname>Schommers</surname><given-names>P</given-names></name><name><surname>Lehmann</surname><given-names>C</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Rybniker</surname><given-names>J</given-names></name><name><surname>Altmüller</surname><given-names>J</given-names></name><name><surname>Mishra</surname><given-names>N</given-names></name><name><surname>Bernardes</surname><given-names>JP</given-names></name><name><surname>Krämer</surname><given-names>B</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name><name><surname>De Domenico</surname><given-names>E</given-names></name><name><surname>Siever</surname><given-names>C</given-names></name><name><surname>Kraut</surname><given-names>M</given-names></name><name><surname>Desai</surname><given-names>M</given-names></name><name><surname>Monnet</surname><given-names>B</given-names></name><name><surname>Saridaki</surname><given-names>M</given-names></name><name><surname>Siegel</surname><given-names>CM</given-names></name><name><surname>Drews</surname><given-names>A</given-names></name><name><surname>Nuesch-Germano</surname><given-names>M</given-names></name><name><surname>Theis</surname><given-names>H</given-names></name><name><surname>Heyckendorf</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Kim-Hellmuth</surname><given-names>S</given-names></name><name><surname>Nattermann</surname><given-names>J</given-names></name><name><surname>Skowasch</surname><given-names>D</given-names></name><name><surname>Kurth</surname><given-names>I</given-names></name><name><surname>Keller</surname><given-names>A</given-names></name><name><surname>Bals</surname><given-names>R</given-names></name><name><surname>Nürnberg</surname><given-names>P</given-names></name><name><surname>Rieß</surname><given-names>O</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Theis</surname><given-names>F</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Backes</surname><given-names>M</given-names></name><name><surname>Aschenbrenner</surname><given-names>AC</given-names></name><name><surname>Ulas</surname><given-names>T</given-names></name><name><surname>Breteler</surname><given-names>MMB</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Kox</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>M</given-names></name><name><surname>Cheran</surname><given-names>S</given-names></name><name><surname>Woodacre</surname><given-names>MS</given-names></name><name><surname>Goh</surname><given-names>EL</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><collab>COVID-19 Aachen Study (COVAS)</collab><collab>Deutsche COVID-19 Omics Initiative (DeCOI)</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Swarm learning for decentralized and confidential clinical machine learning</article-title><source>Nature</source><volume>594</volume><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03583-3</pub-id><pub-id pub-id-type="pmid">34040261</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westermark</surname><given-names>UK</given-names></name><name><surname>Reyngold</surname><given-names>M</given-names></name><name><surname>Olshen</surname><given-names>AB</given-names></name><name><surname>Baer</surname><given-names>R</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name><name><surname>Moynahan</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>7926</fpage><lpage>7936</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.21.7926-7936.2003</pub-id><pub-id pub-id-type="pmid">14560035</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Sobeck</surname><given-names>A</given-names></name><name><surname>Bachrati</surname><given-names>CZ</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Enomoto</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>GW</given-names></name><name><surname>Hoatlin</surname><given-names>ME</given-names></name><name><surname>Hickson</surname><given-names>ID</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>RMI, a new OB-fold complex essential for bloom syndrome protein to maintain genome stability</article-title><source>Genes &amp; Development</source><volume>22</volume><fpage>2843</fpage><lpage>2855</lpage><pub-id pub-id-type="doi">10.1101/gad.1708608</pub-id><pub-id pub-id-type="pmid">18923082</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Powell</surname><given-names>DR</given-names></name><name><surname>Curtis</surname><given-names>DJ</given-names></name><name><surname>Wong</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>From reads to insight: a hitchhiker’s guide to ATAC-seq data analysis</article-title><source>Genome Biology</source><volume>21</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-020-1929-3</pub-id><pub-id pub-id-type="pmid">32014034</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Soares</surname><given-names>J</given-names></name><name><surname>Greninger</surname><given-names>P</given-names></name><name><surname>Edelman</surname><given-names>EJ</given-names></name><name><surname>Lightfoot</surname><given-names>H</given-names></name><name><surname>Forbes</surname><given-names>S</given-names></name><name><surname>Bindal</surname><given-names>N</given-names></name><name><surname>Beare</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name><name><surname>Thompson</surname><given-names>IR</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Benes</surname><given-names>C</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Garnett</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>D955</fpage><lpage>D961</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1111</pub-id><pub-id pub-id-type="pmid">23180760</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yard</surname><given-names>BD</given-names></name><name><surname>Reilly</surname><given-names>NM</given-names></name><name><surname>Bedenbaugh</surname><given-names>MK</given-names></name><name><surname>Pittman</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RNF138 interacts with RAD51D and is required for DNA interstrand crosslink repair and maintaining chromosome integrity</article-title><source>DNA Repair</source><volume>42</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2016.04.006</pub-id><pub-id pub-id-type="pmid">27161866</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Ho</surname><given-names>DJ</given-names></name><name><surname>Neri</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Kulkarni</surname><given-names>T</given-names></name><name><surname>Randhawa</surname><given-names>R</given-names></name><name><surname>Henault</surname><given-names>M</given-names></name><name><surname>Mostacci</surname><given-names>N</given-names></name><name><surname>Farmer</surname><given-names>P</given-names></name><name><surname>Renner</surname><given-names>S</given-names></name><name><surname>Ihry</surname><given-names>R</given-names></name><name><surname>Mansur</surname><given-names>L</given-names></name><name><surname>Keller</surname><given-names>CG</given-names></name><name><surname>McAllister</surname><given-names>G</given-names></name><name><surname>Hild</surname><given-names>M</given-names></name><name><surname>Jenkins</surname><given-names>J</given-names></name><name><surname>Kaykas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>DRUG-seq for miniaturized high-throughput transcriptome profiling in DRUG discovery</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4307</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06500-x</pub-id><pub-id pub-id-type="pmid">30333485</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Meyer</surname><given-names>CA</given-names></name><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>DS</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Nusbaum</surname><given-names>C</given-names></name><name><surname>Myers</surname><given-names>RM</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Model-based analysis of chip-seq (MACS)</article-title><source>Genome Biology</source><volume>9</volume><elocation-id>R137</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clinical significance and biological function of fucosyltransferase 2 in lung adenocarcinoma</article-title><source>Oncotarget</source><volume>8</volume><fpage>97246</fpage><lpage>97259</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.21896</pub-id><pub-id pub-id-type="pmid">29228607</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoppoli</surname><given-names>G</given-names></name><name><surname>Regairaz</surname><given-names>M</given-names></name><name><surname>Leo</surname><given-names>E</given-names></name><name><surname>Reinhold</surname><given-names>WC</given-names></name><name><surname>Varma</surname><given-names>S</given-names></name><name><surname>Ballestrero</surname><given-names>A</given-names></name><name><surname>Doroshow</surname><given-names>JH</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Putative DNA/RNA helicase schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents</article-title><source>PNAS</source><volume>109</volume><fpage>15030</fpage><lpage>15035</lpage><pub-id pub-id-type="doi">10.1073/pnas.1205943109</pub-id><pub-id pub-id-type="pmid">22927417</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuravka</surname><given-names>I</given-names></name><name><surname>Roesmann</surname><given-names>R</given-names></name><name><surname>Sosic</surname><given-names>A</given-names></name><name><surname>Wende</surname><given-names>W</given-names></name><name><surname>Pingoud</surname><given-names>A</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name><name><surname>Göttlich</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Synthesis and DNA cleavage activity of bis-3-chloropiperidines as alkylating agents</article-title><source>ChemMedChem</source><volume>9</volume><fpage>2178</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201400034</pub-id><pub-id pub-id-type="pmid">24616300</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuravka</surname><given-names>I</given-names></name><name><surname>Roesmann</surname><given-names>R</given-names></name><name><surname>Sosic</surname><given-names>A</given-names></name><name><surname>Göttlich</surname><given-names>R</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Bis-3-chloropiperidines containing bridging lysine linkers: influence of side chain structure on DNA alkylating activity</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>23</volume><fpage>1241</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2015.01.050</pub-id><pub-id pub-id-type="pmid">25693786</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuravka</surname><given-names>I</given-names></name><name><surname>Sosic</surname><given-names>A</given-names></name><name><surname>Gatto</surname><given-names>B</given-names></name><name><surname>Göttlich</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Synthesis and evaluation of a bis-3-chloropiperidine derivative incorporating an anthraquinone pharmacophore</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>25</volume><fpage>4606</fpage><lpage>4609</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.08.042</pub-id><pub-id pub-id-type="pmid">26342869</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78012.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Murim</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.02.21.481294" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.02.21.481294"/></front-stub><body><p>To test differential anticancer drug effects on different tissue types, and to understand drug response mechanism, the authors set up a series of RNA-seq and ATAC-seq experiments on drug responsive and non-responsive cell lines. Then they conducted bioinformatic analyses to pinpoint networks that are altered in responsive vs non-responsive cell lines. Remarkably, they used their analytic results to calculate tumor- and sample-specific response to the drug.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78012.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Zhou</surname><given-names>Zilu</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>University of Pennsylvania</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Pearl</surname><given-names>Jocelynn</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/028gkba61</institution-id><institution>Lyell Immunopharma</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.02.21.481294">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.02.21.481294v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Decoding mechanism of action and susceptibility to drug candidates from integrated transcriptome and chromatin state&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Murim Choi as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Mone Zaidi as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Zilu Zhou (Reviewer #2); Jocelynn Pearl (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The reviewers thought that the quality of the manuscript is high, but also thought that it contains several aspects of potential improvements to assure publication in <italic>eLife</italic>. To briefly summarize their concerns:</p><p>1) Design aspect: biological and clinical performance of 3-CePs is not clearly described. Is there any data that illustrates that HCT-15 is low-sensitivity vs BxPC-3 is high-sensitivity?</p><p>2) Analytic aspect: is this approach capable of finding signals that are already constitutively expressed in different cell lines? Need more explanation for vCocena and hCoCena, and what are their differences with CoCena2. Were the tests corrected for multiple testing?</p><p>3) Application aspect: What about its prediction accuracy within an individual cancer subtype? Will it achieve high prediction accuracy on intra-tumor type heterogeneity? Can the algorithm be applied to other drugs in this same class?</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The crosswise approach is not easily comprehendible. It appears to be a network analysis on the union of genes from RNA-seq and ATAC-seq. I wonder if the introduction can be more clear and state uniqueness compared to existing approaches.</p><p>Overall, figure quality is high. However, color coding in figures (cell lines, timepoint, drugs, etc) is unique but not intuitive. Therefore, I had to refer to legends all the way to the last figure. I would suggest changing the color scheme to more intuitively or just use numbers/texts.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Overall I found this manuscript very interesting to read and significant to the field. However, please consider the following questions/comments:</p><p>1. Authors mentioned that HCT-15 is low-sensitivity vs BxPC-3 is high-sensitivity. Is there any data that illustrates this point? Or any description of the phenotype after treatment?</p><p>2. Can the authors describe more about vCocena and hCoCena in Method/Supplement, and what are their differences with CoCena2? I wasn't able to find the answer from the provided citation.</p><p>3. I am also confused about Figure 5B panel 1 on GFC. I thought GFC is a relative fold change compared to treatment to control. What is the control group in this case to calculate GFC?</p><p>4. The pink module is clearly of interest as it showcases the necessity of this multi-omic approach. More generally, can we label all the modules that are only identifiable cross-wise but not by single omic? Can we show a few more detailed examples here? Why are they identified now but not by the single omics approach?</p><p>5. The prediction algorithm at the end shows good prediction power across cancer types. What about its prediction accuracy within an individual cancer subtype? Will it achieve high prediction accuracy on intra-tumor type heterogeneity?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>I enjoyed reading your work and the approach you took to integrating multi-omics data to better understand the mechanism of action and epigenetic signatures of 3-CePs in cancer cell lines. The manuscript was clearly written, and I appreciated the thorough results and methods sections which allowed me to clearly follow the majority of the steps taken.</p><p>As for major revisions, I believe it would be valuable if the authors would test their sensitivity model for compound B in addition to compound M in cell lines described on page 12 and in Figure 6D.</p><p>It is great to see your work in this space and I am hopeful that it further strengthens the use of these data types and analysis methods for improving the drug development process. I will include my general thoughts and suggestions below.</p><p>General Thoughts</p><p>The paper is long – especially the Results section. But I think for this style of work it is better to have a longer, more thoroughly described results and methods section than to leave out key details.</p><p>I would prefer if the paper included p-values for key findings in the text of the article instead of having to locate them in the supplement or figures. I did not see FDRs or q values mentioned throughout the paper/findings – were these calculated? Was there a reason the authors chose to report p-value&lt;0.05 findings as opposed to an FDR/q-value threshold? I find that with gene set enrichment analyses, it can be important to use FDR.</p><p>With regards to the crosswise integration method performed, the authors describe a threshold minimum of 15 nodes per cluster on page 23, line 757 of the manuscript. How was this threshold selected? It would be helpful to mention the total sample size input for constructing the network in these sections.</p><p>For the sensitivity signature, the authors selected LASSO regression – did the authors consider linear regression? How was LASSO chosen?</p><p>For the genes included in the perturbation-informed signature (294 up, 170 genes down), what was the p-value and fold change thresholds used?</p><p>For the sensitivity score (described page 12) – do the authors think that this is the ideal model for calculating a sensitivity score? Did they play around with changing the input for the sensitivity model or the model itself? It would be helpful to understand in greater detail why the authors felt that this was the best input for the model.</p><p>The validation of the sensitivity prediction on cancer cell lines is given a short, one-sentence description in the results. This could be better explained.</p><p>In the discussion and in other locations in the text, the authors describe their approach as 'efficient and versatile' which I think generally ignores the fact that this required next-generation sequencing, two assay types (RNA-seq, ATAC-seq) and in-depth systems biology approaches. Is the argument that the network model is now versatile in that it can be applied to other drugs in this same class? Or that the approach can be borrowed by other groups for other classes of drugs and sample types?</p><p>In the methods section, there were a few details I would like to see added. Product numbers including the ATCC product #s, propidium iodide product #, RNA tape station assay. EDTA concentration in ATAC-seq. For clarity, I recommend breaking the RNAseq and ATACseq methods sections apart. Please also include the sample numbers per group that were sequenced. This was hard to find.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78012.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The reviewers thought that the quality of the manuscript is high, but also thought that it contains several aspects of potential improvements to assure publication in eLife. To briefly summarize their concerns:</p><p>1) Design aspect: biological and clinical performance of 3-CePs is not clearly described. Is there any data that illustrates that HCT-15 is low-sensitivity vs BxPC-3 is high-sensitivity?</p></disp-quote><p>We apologize for not being clear enough when introducing previous findings on the differential sensitivity of HCT-15 and BxPC-3 cancer cell lines to 3-CePs. We now include an introduction to the previous work done by our lab in the revised manuscript (Carraro et al., 2019, Helbing et al., 2020) showing preferential activity of these agents against the pancreatic cancer cell line in both 2D and 3D cancer models (see lines 71-74, 128-129).</p><disp-quote content-type="editor-comment"><p>2) Analytic aspect: is this approach capable of finding signals that are already constitutively expressed in different cell lines?</p></disp-quote><p>We thank the reviewers for pointing out such an interesting concept. The premise for the developed approach is that factors determining the overall cellular sensitivity to a treatment must be determined by basal <italic>intrinsic</italic> characteristics of the cell line. For this reason, we built the sensitivity signature on basal transcriptome profiles, where we prioritized a subset of genes on perturbational evidence (<italic>perturbation-informed basal signature</italic>).</p><p>Beyond signature genes, we show in <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> the results of a GSEA analysis on the whole overlap (300 genes) between DE genes from the baseline comparison (BxPC-3 ctrl vs HCT-15 ctrl) and those from the 6 h M treatment comparison, in the sensitive cell line (BxPC-3 M 6 h vs BxPC-3 ctrl). As expected, pathways like ribosome biogenesis, ROS metabolism, UPR also arise, attesting that genes activated in response to the treatment also have a constitutively different expression in unperturbed cells.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>GSEA analysis on the whole overlap (300 genes) between DE genes from the baseline comparison (BxPC-3 ctrl vs HCT-15 ctrl) and those from the 6 h M treatment comparison, in the sensitive cell line (BxPC-3 M 6 h vs BxPC-3 ctrl).</title><p>Gene ratio is defined as the count of genes belonging to the specific GO term over the whole DE genes input.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78012-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>Need more explanation for vCocena and hCoCena, and what are their differences with CoCena2.</p></disp-quote><p>We apologize to the reviewers for not having properly described the difference between CoCena and the other two horizontal and vertical approaches. We now included a more detailed description in the Methods section (from line 894) as well as in the main text (lines 393-400).</p><p>Briefly, vCoCena and hCoCena are extensions of the original CoCena pipeline for co-expression network analysis aiming at integrating multiple layers of data in one network. hCoCena, first reported in <italic>Aschenbrenner et al., Genome Medicine, 2021</italic>, integrates CoCena networks calculating the correlation between identical features (<italic>genes</italic>) in distinct datasets, making it the ideal tool for integrating different layers of the same omic type. To integrate multi-omics datasets, we further developed and report here vCoCena. A more extended description is provided in Results and Methods sections (from line 894).</p><disp-quote content-type="editor-comment"><p>Were the tests corrected for multiple testing?</p></disp-quote><p>We apologize, if this was not sufficiently described. We specified corrected p values and the applied correction method wherever appropriate throughout the manuscript. To make this more visible, we included a small note in the main text (lines 181, 306, 490, 593), besides having it further specified in the Methods section and figure legends (lines 826, 833, 868, 953, 1042, 1126, 1129, 1135, 1146, 1191, 1197). As specifically asked by Reviewer 3, q values for GSEA on the whole GO dataset are also available in Supplementary files for each biological term. Multiple testing was not applied to FGSEA on gene expression log2FC ranks, being these enrichments inspected on selected GO terms according to the results on the upstream analysis.</p><disp-quote content-type="editor-comment"><p>3) Application aspect: What about its prediction accuracy within an individual cancer subtype? Will it achieve high prediction accuracy on intra-tumor type heterogeneity?</p></disp-quote><p>We thank the reviewers for this interesting question. We now tested the prediction on individual cancer subtypes separately, showing a robust predictive potential (Figure 6 —figure supplement 2 A).</p><disp-quote content-type="editor-comment"><p>Can the algorithm be applied to other drugs in this same class?</p></disp-quote><p>To address this extremely important point, that we agree with the reviewer would be key to prove the versatility of our approach, we further applied the pipeline to the prediction of cancer cell lines’ sensitivity to cisplatin, a thoroughly reported broad-acting chemotherapeutic also acting as a DNA damaging agent. Results strongly supported the broad applicability of our approach, which was able to predict sensitivity to this reference drug with extremely high accuracy.</p><p>The inclusion of this other compound allowed us to further improve the prediction pipeline: we realized that a more valuable and balanced vertical network construction could be achieved when equilibrating the input of DE and DAR-associated genes from the RNA-seq and ATAC-seq analyses. This threshold was set to the top 1000 most variable DE genes from RNA-seq and the top 1000 most variable DAR-associated genes from ATAC-seq (instead of all DE and DARs). This allowed to prevent, and this was more evident in the cisplatin dataset, that the ATAC-seq layer could take over the RNAseq one in the final signature construction, just due to the initial much higher number of input entries. Of course, this implied to revise both the CoCena and prediction Figure 5 and 6, with overall analogue findings and an uncompromised prediction goodness. Beyond adjusting the prediction workflow as explained, we also updated the promoter annotation of ATAC-seq peaks to a newer version. This is the reason for the slight changes in Figure 4, which indeed actually improved the overall biological findings.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The crosswise approach is not easily comprehendible. It appears to be a network analysis on the union of genes from RNA-seq and ATAC-seq. I wonder if the introduction can be more clear and state uniqueness compared to existing approaches.</p></disp-quote><p>We apologize to the reviewer for not including sufficient details in describing the difference between the already existing CoCena network approach and the other two approaches, namely horizontal and vertical approaches. We now included a more detailed description not only in the Methods section (from line 894) but also in the main text as suggested by the reviewer (lines 393-400).</p><p>Briefly, vCoCena and hCoCena are extensions of the original CoCena pipeline for co-expression network analysis aiming at integrating multiple layers of data in one network. hCoCena, first reported in <italic>Aschenbrenner et al., Genome Medicine, 2021</italic>, integrates CoCena networks calculating the correlation between identical features (<italic>genes</italic>) in distinct datasets, making it the ideal tool for integrating different layers from the same omic technology. To integrate multi-omics datasets, we further developed and report here vCoCena. A more extended description is provided in the Methods section (from line 894).</p><disp-quote content-type="editor-comment"><p>Overall, figure quality is high. However, color coding in figures (cell lines, timepoint, drugs, etc) is unique but not intuitive. Therefore, I had to refer to legends all the way to the last figure. I would suggest changing the color scheme to more intuitively or just use numbers/texts.</p></disp-quote><p>To make the figures reading more intuitive, we included explicit texts besides color coding for each condition in all figure panels where needed (e.g. Figures 1 C, D; 3 A, C; 5 B).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Overall I found this manuscript very interesting to read and significant to the field. However, please consider the following questions/comments:</p><p>1. Authors mentioned that HCT-15 is low-sensitivity vs BxPC-3 is high-sensitivity. Is there any data that illustrates this point? Or any description of the phenotype after treatment?</p></disp-quote><p>We apologize for not being clear enough when introducing previous findings on the differential sensitivity of HCT-15 and BxPC-3 cancer cell lines to 3-CePs. We now included an introduction to the previous work done by our lab in the revised manuscript showing preferential activity of these agents against the pancreatic cancer cell line in both 2D and 3D cancer models (see lines 71-74, 128-129.</p><disp-quote content-type="editor-comment"><p>2. Can the authors describe more about vCocena and hCoCena in Method/Supplement, and what are their differences with CoCena2? I wasn't able to find the answer from the provided citation.</p></disp-quote><p>We apologize to the reviewer for not having properly described the difference between CoCena and the other two horizontal and vertical approaches. We now included a more detailed description in the Methods section (from line 894) as well as in the main text (lines 393-400).</p><p>Briefly, vCoCena and hCoCena are extensions of the original CoCena pipeline for co-expression network analysis aiming at integrating multiple layers of data in one network. hCoCena, first reported in <italic>Aschenbrenner et al., Genome Medicine, 2021</italic>, integrates CoCena networks calculating the correlation between identical features (<italic>genes</italic>) in distinct datasets, making it the ideal tool for integrating different layers of the same omic type. To integrate multi-omics datasets, we further developed and report here vCoCena. A more extended description is provided in Results and Methods sections (from line 894).</p><disp-quote content-type="editor-comment"><p>3. I am also confused about Figure 5B panel 1 on GFC. I thought GFC is a relative fold change compared to treatment to control. What is the control group in this case to calculate GFC?</p></disp-quote><p>Apologies to the reviewer for not being clear enough. GFC is the <italic>Group Fold Change</italic> which was originally described in Aschenbrenner et al., Genome Medicine 2021 as follows: “To assess the expression strength of the found gene clusters in the different studied conditions, the group fold changes (GFCs) of the conditions are calculated for each gene by calculating the mean expression of a gene over all samples and then computing the fold change of the mean gene expression within each condition from the overall mean.” To make this more clear for the reader of the current manuscript, we now included the detailed definition of GFC in the Methods section at line 935.</p><disp-quote content-type="editor-comment"><p>4. The pink module is clearly of interest as it showcases the necessity of this multi-omic approach. More generally, can we label all the modules that are only identifiable cross-wise but not by single omic? Can we show a few more detailed examples here? Why are they identified now but not by the single omics approach?</p></disp-quote><p>We thank the reviewer for this suggestion. In the revised version of the network, the <italic>steelblue</italic> module was reported to illustrate the cross-wise integration adding novel insights into the mechanism of response (lines 451-464). The now so-called <italic>steelblue</italic> module has indeed a similar regulation to the previous <italic>pink</italic> one. We further described in the main text also the other integrated and single-omic modules from vCoCena to further point out the advantage of such network analysis (see lines 427-450).</p><p>The overall added value of using vCoCena compared to the initial single layer non-network based analysis consists in the ability to take apart genes with the same regulation pattern, both inside one omic layer and between layers. Grouping transcripts and promoters into the same regulatory module allows to maximize the ratio of hits producing enrichments otherwise not recognizable from separate analysis, due to insufficient representation in the single omics (this is a matter of set size and ratio in this set). Starting both the transcriptome and chromatin horizontal networks from the union of the top 1000 variable genes from both RNA and ATAC-seq datasets, further enhances the multi-omic integration.</p><disp-quote content-type="editor-comment"><p>5. The prediction algorithm at the end shows good prediction power across cancer types. What about its prediction accuracy within an individual cancer subtype? Will it achieve high prediction accuracy on intra-tumor type heterogeneity?</p></disp-quote><p>We thank the reviewer for this interesting question. We now tested the prediction on individual cancer subtypes separately, showing a robust predictive potential (see figure 6 —figure supplement 2 A).</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>I enjoyed reading your work and the approach you took to integrating multi-omics data to better understand the mechanism of action and epigenetic signatures of 3-CePs in cancer cell lines. The manuscript was clearly written, and I appreciated the thorough results and methods sections which allowed me to clearly follow the majority of the steps taken.</p></disp-quote><p>We thank the reviewer for these very positive statements.</p><disp-quote content-type="editor-comment"><p>As for major revisions, I believe it would be valuable if the authors would test their sensitivity model for compound B in addition to compound M in cell lines described on page 12 and in Figure 6D.</p></disp-quote><p>To further validate the versatility of our platform beyond the specific class of compounds, we further applied the pipeline to the prediction of cancer cell lines’ sensitivity to cisplatin, a thoroughly reported broad-acting chemotherapeutic also acting as a DNA damaging agent. Results strongly supported the broad applicability of our approach, which was able to predict sensitivity to this reference drug with extremely high accuracy.</p><disp-quote content-type="editor-comment"><p>It is great to see your work in this space and I am hopeful that it further strengthens the use of these data types and analysis methods for improving the drug development process. I will include my general thoughts and suggestions below.</p><p>General Thoughts</p><p>The paper is long – especially the Results section. But I think for this style of work it is better to have a longer, more thoroughly described results and methods section than to leave out key details.</p></disp-quote><p>We thank the reviewer for the positive comment. We also believe that, given the complexity of specific passages in our workflow, it is better to spend a few words more than to take concepts for granted.</p><disp-quote content-type="editor-comment"><p>I would prefer if the paper included p-values for key findings in the text of the article instead of having to locate them in the supplement or figures. I did not see FDRs or q values mentioned throughout the paper/findings – were these calculated? Was there a reason the authors chose to report p-value&lt;0.05 findings as opposed to an FDR/q-value threshold? I find that with gene set enrichment analyses, it can be important to use FDR.</p></disp-quote><p>We apologize with the reviewer, if this was not sufficiently described. We specified corrected p values and the applied correction method wherever appropriate throughout the manuscript. To make this more visible, we included a small note in the main text (lines 181, 306, 490, 593), besides having it further specified in the Methods section and figure legends (lines 826, 833, 868, 953, 1042, 1126, 1129, 1135, 1146, 1191, 1197). q values for GSEA on the whole GO dataset are also available in Supplementary Data tables for each biological term. Multiple testing was not applied to FGSEA on gene expression log2FC ranks, being these enrichments inspected on selected GO terms according to the results on the upstream analysis. We decided to employ GSEA cursorily in different steps of the analysis in order to get a preliminary overview of possible pathways to investigate. The high redundancy observed among significant (p&lt;0.05) terms (see Supplementary file 10) further confirmed the consistency of emerged biological processes.</p><disp-quote content-type="editor-comment"><p>With regards to the crosswise integration method performed, the authors describe a threshold minimum of 15 nodes per cluster on page 23, line 757 of the manuscript. How was this threshold selected? It would be helpful to mention the total sample size input for constructing the network in these sections.</p></disp-quote><p>This is a very valid point. We now report the hit input size upon revising our strategy also in the Result section (line 411) besides having them specified in the Methods section (line 925). Concerning the 15 nodes threshold, we inspected different values from a minimum of 10 and chose such threshold empirically with the overall goal to maximize the number of detected modules with specific regulation patterns (also in horizontally integrated networks) without compromising the possibility to get efficient functional enrichments.</p><disp-quote content-type="editor-comment"><p>For the sensitivity signature, the authors selected LASSO regression – did the authors consider linear regression? How was LASSO chosen?</p></disp-quote><p>We thank the reviewer for this comment. In essence, we agree with the reviewer that probably a simple linear regression without parameter shrinking would also be an option. However, we chose to use l1-regularized linear regression (the lasso), because it is an excellent option in high-dimensional settings. We have recently compared many different approaches in a similar but not identical setting (see Warnat-Herresthal et al., iScience 2020) and could show that LASSO led to very robust results when using transcriptome data in a clinical setting. Based on this experience, we used LASSO. We hope that the reviewer can agree with us that we would not extend the work here to introduce additional other regression models for benchmarking since it would further lengthen the manuscript and would somewhat distract from the main message of the manuscript.</p><disp-quote content-type="editor-comment"><p>For the genes included in the perturbation-informed signature (294 up, 170 genes down), what was the p-value and fold change thresholds used?</p></disp-quote><p>Based on the question of the reviewer and with the new data about Cisplatin integrated into the manuscript we have further improved this section. The M signature was obtained by intersecting genes coming from the selected vCoCena modules with DE genes from the comparison between HCT-15 and BxPC-3 untreated controls using a min abs(log2FC) = 1 and padj &lt; 0.01 to strictly select the most significant hallmark genes. Updated information on the final signature size after revising (both for M and cisplatin) have now been included also in the main text (line 490, 495, 593, 595) besides having it specified in the Methods section (lines 974, 975).</p><disp-quote content-type="editor-comment"><p>For the sensitivity score (described page 12) – do the authors think that this is the ideal model for calculating a sensitivity score? Did they play around with changing the input for the sensitivity model or the model itself? It would be helpful to understand in greater detail why the authors felt that this was the best input for the model.</p></disp-quote><p>This is a very interesting question. Considering the promising predictive outcome, we would argue that the score itself was efficient enough to describe sensitivity. To further support this observation, we now further validated it using a well-established DNA damaging anticancer drug, cisplatin. As we see the experimental validation to be the strongest support for the usefulness of the model, we opted not to further explore the model itself at this time. But we would like to thank the reviewer for this excellent idea and we definitely will continue on the modeling part in a follow-up more computational project to see whether the model itself can be further improved without losing the simplicity of the selected score type. One could also think about extending the model in future developments to scRNA-seq and scATAC-seq data as input. However, we feel that this would be beyond the current scope of the manuscript and we hope the reviewer can agree with this approach.</p><disp-quote content-type="editor-comment"><p>The validation of the sensitivity prediction on cancer cell lines is given a short, one-sentence description in the results. This could be better explained.</p></disp-quote><p>We thank the reviewer for this comment and we addressed this aspect now in the text as suggested at lines 516-521.</p><disp-quote content-type="editor-comment"><p>In the discussion and in other locations in the text, the authors describe their approach as 'efficient and versatile' which I think generally ignores the fact that this required next-generation sequencing, two assay types (RNA-seq, ATAC-seq) and in-depth systems biology approaches. Is the argument that the network model is now versatile in that it can be applied to other drugs in this same class? Or that the approach can be borrowed by other groups for other classes of drugs and sample types?</p></disp-quote><p>Again, these are very valid points by the reviewer. As outlined earlier (see above), we are convinced that – while currently still in its infancy and novel – multi-omics approaches together with in-depth systems biology approaches will revolutionize biology and medicine and will guide the way towards precision medicine (as much as physics was transformed by mathematics in the 20th century, biology and medicine will be transformed by data sciences). However, we agree with the reviewer that we should be more explicit and outspoken. Therefore, to address this extremely important point, and to further illustrate versatility of the approach, we included another well-known drug, cisplatin (as another DNA damaging agent with well-known clinical efficacies), illustrating how efficient our approach predicts cancer cell lines’ sensitivity to cisplatin. We therefore are convinced that the proposed approach is both versatile in being applicable to other drugs and, as a consequence, generalizable to other diseases and target cell populations. We made changes accordingly in lines 695-697.</p><disp-quote content-type="editor-comment"><p>In the methods section, there were a few details I would like to see added. Product numbers including the ATCC product #s, propidium iodide product #, RNA tape station assay. EDTA concentration in ATAC-seq. For clarity, I recommend breaking the RNAseq and ATACseq methods sections apart. Please also include the sample numbers per group that were sequenced. This was hard to find.</p></disp-quote><p>We added these details as suggested by the reviewer in the Methods section (715-717, 750, 797, 799).</p></body></sub-article></article>